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ABSTRACT

Accumulation of toxic protein assemblies and damaged mitochondria are key features of
neurodegenerative diseases, which arise in large part from clearance defects in the
autophagy-lysosome system. The autophagy cargo receptor p62/SQSTM1 plays a major
role in the clearance of ubiquitinated cargo through Ser403 phosphorylation by multiple
kinases. However, no phosphatase is known to physiologically dephosphorylate p62 on
this activating residue. RNAi-mediated knockdown and overexpression experiments
using genetically encoded fluorescent reporters and defined mutant constructs in cell
lines, primary neurons, and brains show that SSH1, the canonical cofilin phosphatase,
mediates the dephosphorylation of phospho-Ser403-p62, thereby impairing p62 flux and
phospho-tau clearance. The inhibitory action of SSH1 on p62 is fully dependent on p62
Ser403 phosphorylation status and is separable from SSH1-mediated cofilin activation.
These findings reveal a bipartite action of SSH1 on p62 independent of cofilin and
implicate an inhibitory role of SSH1 in p62-mediated clearance of autophagic cargo,
including phospho-tau.

Abbreviations: SSH1: Slingshot Homolog-1; p62/SQSTM1 or p62: sequestosome 1;
LC3: microtubule associated protein 1 light chain 3; Aβ42O: Amyloid beta 1-42 oligomers;
siRNA: small interfering RNA; PLA: proximity ligation assay; shRNA: short hairpin RNA;
AAV: Adeno-associated virus
v

CHAPTER 1

INTRODUCTION

Accumulation of toxic protein assemblies and dysfunctional mitochondria are associated
with synaptic and neuronal loss in multiple neurodegenerative disorders. Such
accumulations are thought to arise in large part from clearance deficits in the autophagylysosome system (Alvarez-Arellano et al., 2018; Boland et al., 2008; Bordi et al., 2016;
Feng et al., 2019; Tanji et al., 2014; Zare-Shahabadi et al., 2015; Zhang and Zhao, 2015).
Selective autophagy is a major type of autophagy characterized by the recognition and
degradation of specific cargo, such as damaged organelles, misfolded proteins, or
invading pathogens (Kimmelman and White, 2017; Levine et al., 2011; Menzies et al.,
2017; Mizushima, 2018). Mitophagy is a form of selective autophagy that specifically
removes damaged mitochondria from cells, which is vital to mitochondrial quality control
and cellular health (Lemasters, 2005, 2014). In the proceeding chapters, I describe the
relevant literature on Alzheimer’s disease (AD) and related disorders (ADRD), reported
deficits in mitochondrial function and autophagy in AD including the role of p62 and cofilin,
and how a phosphatase called Slingshot Homolog-1 (SSH1) plays an inhibitory role in the
autophagic clearance of misfolded tau and damaged mitochondria. This study therefore
highlights a wholly new function of SSH1 independent of its canonical role in cofilin
activation.
1

Neurodegenerative Disorders
Neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD), and Frontotemporal dementia (FTD), are age-related progressive degenerative
disorders of the brain, which have become among the leading causes of death as the
aging population increases (Przedborski et al., 2003). While all neurodegenerative
disorders ultimately result in the loss of synapses and neurons, such loss occurs in a
characteristic spatiotemporal manner in different neurodegenerative diseases, thereby
leading to different clinical symptoms. For example, dopaminergic neurons of the
substantia nigra are preferentially lost in PD, resulting in Parkinsonian motor symptoms
(Greffard et al., 2006), whereas neurons of the frontal cortex are preferentially lost in FTD,
leading to impairments in frontal executive function (Neary et al., 1998; Saing et al., 2012).
In addition, distinct neurodegenerative diseases exhibit key molecular signatures in brain,
exemplified by the accumulation of specific pathological proteins

– namely

proteinopathies. Classical examples of these include Aβ (plaques) and tau (tangles) in
AD (Bloom, 2014; Braak and Braak, 1991, 1995; Gomez-Isla et al., 1997), tau or TDP-43
in FTD (Chornenkyy et al., 2019; Gao et al., 2019; Keating, 2008), α-synuclein (Lewy
bodies) in PD (Bethlem and Den Hartog Jager, 1960), and Huntingtin protein aggregates
in Huntington’s disease (HD) (Scherzinger et al., 1997). Among a multitude of
proteinopathies, tauopathy is perhaps the most prevalent in neurodegenerative
conditions, as tauopathy is not unique to AD but is also a key feature of Frontotemporal
lobar degeneration (FTLD-tau), Pick’s disease, Corticobasal degeneration, and others
(Dickson et al., 2011; Kovacs, 2015; Lee et al., 2001; Spillantini and Goedert, 2013).
Similarly, synucleinopathy is not only present in PD but is also found in Multiple system
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atrophy (MSA) (Lantos, 1998) and other Lewy body disorders such as Lewy body
dementia (LBD) (Irizarry et al., 1998). Hence, all neurodegenerative disorders are
characterized by the accumulation of protein assemblies, which are associated with
mitochondrial abnormalities (Swerdlow et al., 2014), neuroinflammation (Carret-Rebillat
et al., 2015), synapse loss (Dejanovic et al., 2018; Wu et al., 2019; Yin et al., 2016), and
neuronal degeneration (Dugger et al., 2014; Evidente et al., 2011; Frigerio et al., 2011;
Gibb and Lees, 1988; Milenkovic and Kovacs, 2013; Schmitt et al., 2000). However,
neuropathological evaluation at autopsy is still the gold standard for diagnosis, as many
patients have mixed clinical and pathological features characteristic of more than one
neurodegenerative condition.

Alzheimer’s Disease
Alzheimer’s disease (AD) is an age-associated neurodegenerative disease and the most
common form of dementia, which accounts for more than 65% of all dementias (Kemle
and Ackermann, 2018; Small et al., 1997). Symptoms include memory loss, cognitive
dysfunction, language disturbances, as well as mood and behavioral changes (Ballard et
al., 2011). AD is the third leading cause of death in the United states, affecting more than
5 million Americans today (Hurd et al., 2013).
AD was first introduced by Dr. Alois Alzheimer, a Bavarian psychiatrist, in 1906 at
a meeting in Munich. The original patient, a fifty-year-old woman named Auguste Deter,
was reported with key clinical features, such as progressive memory loss, cognitive
dysfunction, behavioral changes, and the loss of language ability (Alzheimer et al., 1995).
Upon her death and autopsy, Dr. Alzheimer described ‘miliary foci’ and ‘striking changes
3

in neurofibrils’ in brain (Alzheimer et al., 1995). However, there was little progress in the
study of AD for many decades until Robert Terry in the United States and Michael Kidd
in England described the two hallmarks of AD, the senile plaques and neurofibrillary
tangles, in the 1960s (Kidd, 1964; Terry, 1963), which we now know as accumulations of
the amyloid β (Aβ) peptide in plaques and hyperphosphorylated tau in neurofibrillary
tangles (Selkoe, 2001). These are also essentially the same changes described as
‘miliary foci’ and ‘neurofibrils’ by Dr. Alzheimer.
The amyloid precursor protein (APP) is a single-pass type I transmembrane protein
(Thinakaran and Koo, 2008). Although the precise physiological function of APP remains
unclear (Oh et al. 2009), Aβ is a peptide derived from APP through 2 sequential proteolytic
cleavages by the BACE1 enzyme (β-secretase) and the presenilin complex (-secretase)
(Holtzman et al., 2012; Oda et al., 2010; Thinakaran and Koo, 2008). Neurofibrillary
tangles and neuropil threads are intracellular inclusions largely composed of the
microtubule-associated protein tau (MAPT) in an hyperphosphorylated form (Goedert,
1993), which are seen as paired helical filament (PHFs) under an electron microscope
(Crowther and Wischik, 1985). In addition to Aβ and tau, multiple lines of evidence
indicate that AD pathogenesis is vastly more complex and includes proteinopathies
typically associated with other neurodegenerative diseases, such as Amyotrophic Lateral
Sclerosis (ALS), FTLD, and PD (Neumann, 2009; Zhang and Zhao, 2015). For example,
ALS-associated TDP-43 inclusions are widespread in 59% of AD (Josephs and Nelson,
2015), PD-associated -synucleinopathy is present in >25% of AD (Zhang and Zhao,
2015), and ubiquitin binding protein p62-positive inclusions are present colocalized with
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ubiquitin in AD, FTLD-ALS, and PD brains (Arai et al., 2003; Kuusisto et al., 2001, 2002;
Rea et al., 2014; Salminen et al., 2012), suggesting a failure of p62-mediated clearance.

Genetic Basis of Alzheimer’s Disease and the Amyloid Cascade Hypothesis
In the past decades, great progress has been made in unraveling the genetic basis of
AD. While less than 5% of AD cases are familial forms with autosomal dominant mode of
transmission (Schott et al., 2002), such discoveries have yielded valuable insights to the
early pathogenesis of AD (Hardy and Allsop, 1991). Specifically, these genetic
discoveries have strongly supported the amyloid cascade hypothesis (Hardy and Allsop,
1991), which states that the accumulation of Aβ plays an early causal role in AD,
progressively driving other AD features such as hyperphosphorylation of tau,
mitochondrial dysfunction, neuroinflammation, and neuronal degeneration. The familial
forms of AD are known as familial early-onset AD (FAD) owing to their earlier age of
disease onset, which is typically before the age of 65 (van Duijn et al., 1993).
Many mutations in several genes have been identified that co-segregate with
autosomal dominant FAD, including in genes coding for the Amyloid precursor protein
(APP), Presenilin-1 (PSEN1), and Presenilin-2 (PSEN2). Although the precise
physiological function of APP remains unclear (Senechal et al., 2007), Aβ is largely
produced when APP is routed into BACE-1-containing acidic organelles via clathrindependent endocytosis from the cell surface (Das et al., 2013; Koo and Squazzo, 1994),
which is where the vast majority of BACE1 cleavage of APP occurs (Vassar et al., 1999).
Interestingly, palmitoylation-dependent BACE1 targeting to cholesterol-rich raft
microdomains is critical for neuronal activity-dependent Aβ production and Aβ deposition
5

(Andrew et al., 2017). The non-amyloidogenic α-secretase processing of APP by
ADAM10/17 largely occurs on the plasma membrane and such processing is reduced by
APP endocytosis (Haass et al., 2012; Koo and Squazzo, 1994). The newly generated Aβ
either remains associated within membrane compartments and lipid raft structures or is
released into the extracellular space. All FAD mutations in APP (on Chromosome 21
q21.3-q22.05) identified thus far are concentrated near the β-secretase or -secretase
cleavage sites in APP, which lead to increases in total Aβ or the more pathogenic Aβ42
peptide (Goate, 1998), thereby supporting the amyloid hypothesis. Presenilins constitute
the catalytic component of the -secretase complex (Cervantes et al., 2004). Of ~200 FAD
mutations in PSEN genes identified thus far, all tested PSEN1 (Chromosome 14) or
PSEN2 (Chromosome 1) mutations also increase the ratio of Aβ42 to shorter Aβ peptides
(De Strooper et al., 2012). While Aβ42 is produced at less than 15% in quantity of Aβ40,
Aβ42 aggregates faster and seeds the aggregation of A40 (Glabe, 2008). Transgenic
mice expressing only Aβ40 or Aβ42 cleaved from the familial British and Danish
Dementia-related BRI protein show that Aβ40 alone cannot form aggregates into senile
plaques even by 18 months of age, while Aβ42 expression results in robust accumulation
of senile plaques at 12 months of age. Moreover, BRI-Aβ42 mice crossed with APP
Tg2576 mice expressing the FAD “Swedish” mutation exponentially increases Aβ plaques
in brain (McGowan et al., 2005).
Aβ can exist as soluble monomers, dimers, trimers, and higher order oligomers
before assembling into protofibrils and insoluble amyloid fibrils (Glabe, 2008). Insoluble
Aβ fibrils are enriched with β-sheet secondary structure that can be bound by specific
dyes such as Congo red or thioflavin. Even in their soluble states, Aβ42 and Aβ40 differ

6

in that Aβ42 populates a more stable structured oligomeric state than Aβ40 (Chen and
Glabe, 2006). Soluble Aβ oligomers can promote synaptic dysfunction at subnanomolar
concentrations, and SDS-stable dimers and trimers impair long term potentiation (LTP) in
rats in vivo (Walsh et al., 2002). SDS-resistant Aβ dimers derived from AD brains promote
the hyperphosphorylation of tau and neuritic degeneration in primary hippocampal
neurons also at subnanomolar concentration (Jin et al., 2011). Many other studies have
shown that Aβ promotes the hyperphosphorylation of tau in vitro and in vivo (Avila et al.,
2004; Gendron and Petrucelli, 2009). Aβ also exacerbates tauopathy in transgenic mice
expressing the Frontotemporal Dementia (FTDP-17) tau mutation (Lewis et al., 2000). In
triple transgenic mice expressing APP/tau/presenilin-1 mutations (3xTg), depletion of Aβ
by injection of an antibody directed against Aβ reduces not only Aβ pathology but also
tauopathy (Oddo et al., 2004). These results collectively support the amyloid hypothesis
of AD, indicating that the accumulation of Aβ, when present, serves an early event that
triggers downstream degenerative phenotypes.
Although mutations in APP, PSEN1, and PSEN2 account for the majority of earlyonset FAD, over 95% of AD cases are of the multifactorial sporadic late-onset type, which
cannot be explained by a single gene. Nevertheless, genetic risk factors do play important
roles in late-onset sporadic AD. Of these, the strongest genetic risk factor is the ε4 allele
of the gene coding for Apolipoprotein E (APOE) on Chromosome 19 (Liu et al., 2013).
Compared to the most prevalent ε3 alleles, the ε4 allele increases the risk for AD by ~3fold among hemizygotes and by ~15-fold among homozygotes (DeMattos et al., 2001).
Interestingly, the least prevalent ε2 allele is significantly underrepresented in AD and
plays a protective role against AD pathogenesis (Cacabelos et al., 2012). Further
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supporting the amyloid hypothesis, the apoE4 protein promotes the aggregation of Aβ
more effectively than apoE3 (Kim et al., 2009a; Strittmatter et al., 1993). Therefore, the
strongest genetic components of early-onset FAD and late-onset sporadic AD either
increase total Aβ, the more pathogenic Aβ42 peptide, or aggregation states of Aβ. In
addition to APOE, other genetic factors identified from genome wide association studies
(GWAS) play less significant but nevertheless important roles in AD pathogenesis. These
genes, which have a wide range of functions such as protein trafficking,
neuroinflammation, signal transduction, RNA splicing, transcription, immunity, lipid
metabolism, epigenetics, and synaptic function include ABCA7, BIN1, CR1, CD2AP,
CLU, CASS4, CELF1, EPHA1, FERMT2, HLA-DRB5, INPP5D, MEF2C, MS4A, NME8,
PICALM, PTK2B, SORL1, SlC24A4, TREM2, and ZCWPW1 (Rosenthal and Kamboh,
2014). At present, it is unclear whether such genetic risk factors contain direct and
significant implications for the amyloid cascade hypothesis.

Tauopathy
Diseases associated with the pathological accumulation of tau in neurons and glia are
collectively called tauopathies (Dickson et al., 2011; Kovacs, 2015; Lee et al., 2001;
Spillantini and Goedert, 2013). The microtubule-associated protein tau (MAPT) is
abundantly present in axons. The major function of tau is in the polymerization and
stabilization of microtubules (Binder et al., 1985; Mandelkow and Mandelkow, 2012).
Tauopathy is initiated starting from the detachment of tau from microtubules, which not
only

results

in microtubule

destabilization

but

is also

associated

with

tau

hyperphosphorylation (Wang and Mandelkow, 2016). Microtubule dynamics play
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significant roles in neurite extension, arborization, and dendritic spine morphogenesis
(Coles and Bradke, 2015; Miller and Suter, 2018). In addition, microtubules function as
‘highways’ for transport of proteins and organelles along axons and dendrites. Such
transport is mediated by motor proteins such as kinesin and dynein (Lu and Gelfand,
2017), which is particularly critical in long axons that require anterograde transport of
organelles such as mitochondria and synaptic vesicles as well as retrograde transport of
damaged mitochondria and misfolded proteins for autophagic clearance (Tammineni and
Cai, 2017). Indeed, disruption of axonal transport is thought to play a key role in synaptic
dysfunction in neurodegenerative diseases including AD (De Vos et al., 2008; Kanaan et
al., 2013).
Direct evidence for a causal role of tau in neurodegeneration is found in familial
frontotemporal dementia with Parkinsonism on Chromosome 17 (FTDP-17), in which
mutations in MAPT co-segregate with disease in an autosomal dominant manner (Hutton
et al., 1998). These tau mutations in general increase the propensity of tau to form
aggregates, destabilize microtubules, and increase the state of tau phosphorylation (Buee
et al., 2000). In addition to phosphorylation, however, other post-translational
modifications on tau, such as ubiquitination, nitrification, glycosylation, and acetylation,
are also associated with abnormal tau accumulation in degenerative tauopathies (Cook
et al., 2014; Morishima and Ihara, 1994). Alternative mRNA splicing of exons 2, 3 and 10
produces six major isoforms of tau. Three of them contain four conserved 32 amino acid
repeats (4R-tau) while the other three isoforms contain three repeats (3R-tau) that bind
to microtubules. The relative accumulation of 3R and 4R tau varies in different

9

neurodegenerative tauopathies (Mandelkow and Mandelkow, 2012). Both 3R and 4R tau
are found in AD (Mackenzie et al., 2010).
Tauopathies can be subdivided into primary or secondary tauopathies. Primary
tauopathies refer to neurodegenerative diseases in which tau is believed to be the major
contributing factor to the neurodegenerative process (Josephs, 2017), including FTLDtau, PSP, CBD, and others. In secondary tauopathies, the driving force other than tau is
thought to be primary. This certainly appears to be the case in the majority of FAD, as
mutations APP, PSEN1, and PSEN2 primarily drive A pathology, which in turn, promotes
tauopathy (Hardy et al., 1998). However, it remains to be seen if tauopathy is indeed
secondary in late-onset sporadic AD, as the toxic effects of Aβ require the presence of
tau. Specifically, neurite retraction and progressive neuronal atrophy (Jin et al., 2011;
Rapoport et al., 2002) as well as defects in LTP and axonal transport (Shipton et al., 2011)
are seen when neurons are treated with Aβ but not in neurons derived from tau knockout
mice. Learning and memory impairments are present in mutant APP transgenic mice but
not in the same transgenic mice on a MAPT knockout background (Roberson et al., 2007).
These results together with FTDP-17 mutations in tau clearly indicate that while Aβ can
drive tauopathy, tau alone can drive neurodegeneration, and tau is required for multiple
facets of Aβ-triggered neurotoxicity.

Mitochondrial Dysfunction in AD
Mitochondria are double membraned organelles that are maternally inherited.
Mitochondria are highly dynamic organelles that are constantly undergoing fusion, fission,
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microtubule-based transport, and selective clearance. Such dynamism maintains the
size, shape, number, content, health, and distribution of mitochondria (Patrushev et al.,
2015). The most important role of mitochondria is the production of cellular energy in the
form of adenosine triphosphate (ATP) (Bonora et al., 2012). When electrons flow from a
donor with a lower redox potential to a receptor with a higher redox potential through four
biochemically linked multi-subunit complexes (I, II, III, and IV) and two electron carriers
(coenzyme Q and cytochrome c), energy produced in this process drives ATP synthase
(complex V) to produce ATP by the phosphorylation of ADP. However, reactive oxygen
species (ROS) are also produced during this process from the electron transport chain
(ETC)(Bonora et al., 2012). Excessive ROS production can disrupt normal metabolism,
organelles and induce DNA mutations (Nita and Grzybowski, 2016).
In addition to energy production, mitochondria also play an important role in the
synergistic buffering of calcium ions together with the endoplasmic reticulum (ER)
(Chiarini et al., 2015). When Ca2+ levels increase in the cytosol, mitochondria take up
Ca2+ through the mitochondrial Ca2+ uniporter (MCU), resulting in Ca2+ buffering and
promotion of ATP production (Bezprozvanny and Mattson, 2008). However, if excessive
Ca2+ enters mitochondria (calcium overload), this can result in decreased mitochondrial
membrane potential (MMP) and oxidative stress. This, in turn, can trigger the formation
of the mitochondrial permeability-transition pore (mtPTP) and failure to buffer Ca2+,
leading to secondary excitotoxicity (Hengartner, 2000). Moreover, loss of components of
the electron transport chain (ETC) from mitochondria and release into the cytosol (i.e.
cytochrome c) can occur through the mtPTP, which results in the activation of caspases
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3, 6, 7, 8 and 9, increased ROS production, and mitochondria-mediated apoptosis
(Bossy-Wetzel et al., 1998; Granville et al., 1998; Li et al., 1997a).
One of the earliest pathogenic features of neurons in multiple neurodegenerative
disorders, including AD, is the presence of dysfunctional or damaged mitochondria. This
may in part be due to the longer half-life of mitochondria in neurons versus other cells,
which increases the propensity of neuronal mitochondria to accumulate damage (Kowald
and Kirkwood, 2011). However, many studies have shown that the accumulation of
pathogenic Aβ or tau promotes mitochondrial damage. Specifically, overexpression of
APP/Aβ in rodents increases mitochondrial fragmentation (Cai and Tammineni, 2016). In
cortical samples of AD patients, levels of transcripts coding for fission proteins Drp1 and
Fis1 are elevated, whereas transcripts coding for fusion proteins Opa1, Mfn1, and Mfn2
are significantly decreased (Manczak et al., 2011), thereby disrupting the balance of
mitochondrial fusion and fission. Aβ also disrupts mitochondrial membrane potential,
increases ROS production, impairs mitochondrial respiration, reduces ATP production,
impedes axonal transport of mitochondria, and promotes the opening of the mPTP
(Garcia-Escudero et al., 2013). Tau pathology is also linked to mitochondrial dysfunction.
Transgenic mice expressing the tau P301L mutation show a significant reduction in
complex V and NADH-ubiquinone oxidoreductase activity together as wells as
impairments in mitochondrial respiration and ATP production (David et al., 2005).
Overexpression pathogenic tau leads to a significant decrease in mitochondrial
membrane potential and loss of mitochondrial membrane integrity (Quintanilla et al.,
2009). Moreover, pathogenic tau overexpression in mature hippocampal neurons
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promotes the degeneration of synapses by disrupting mitochondrial transport and ATP
levels at the synapse (Thies and Mandelkow, 2007). (Figure 1)

Autophagy and Mitophagy
Autophagy is a major mechanism of clearing and recycling “waste” from cells, including
misfolded proteins (i.e. tau) and damaged organelles (i.e. mitochondria). Autophagy is
classified into 3 general types: macroautophagy, microautophagy and chaperonemediated autophagy. Microautophagy refers to a process that involves the direct uptake
of soluble or particulate constituents into lysosomes, leading to their degradation (Parzych
and Klionsky, 2014). Chaperone-mediated autophagy (CMA) refers to a chaperonedependent (i.e. Hsc70) selection of soluble cytosolic proteins, which are then targeted to
lysosomes through the binding to the lysosome receptor LAMP-2A (Kaushik and Cuervo,
2012). The most prevalent type of autophagy is macroautophagy, which is further
subdivided into bulk autophagy and selective autophagy. In bulk autophagy, cellular
constituents are recycled to compensate for the lack of nutrients and is thought to be
rather non-selective toward its cargo (Kopitz et al., 1990; Kuma et al., 2004). Unlike bulk
autophagy, however, selective autophagy refers to a process in which the cargo is
specifically recognized by selective autophagy cargo receptors, such as p62/SQSTM1,
NBR1, OPTN, TOLLIP, NDP52 and TAXBP1 (Lazarou et al., 2015; Tumbarello et al.,
2015). While some cargo can bind directly to cargo receptors, most cargo receptors
preferentially bind poly-ubiquitin chains attached to cargo (Kirkin et al., 2009; Slobodkin
and Elazar, 2013). The binding of cargo to selective cargo receptors then promote the
formation of a double membraned autophagophore, which surrounds and engulfs the
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cargo to form the autophagosome. Upon transport and fusion of the autophagosome with
the lysosome (autolysosome), selected cargo is removed by lysosomal hydrolases
(Mauvezin et al., 2016; Tsuboyama et al., 2016).
The assembly of autophagosomes is controlled by a group of autophagyassociated protein (ATG) complexes. The Atg1/ULK1 complex, which contains Ser/Thr
kinases ULK1 and ULK2 as well as ATG13, FIP200/RB1CC1 and ATG101, is involved in
the initiation step (Wang et al., 2018). The Class III phosphatidylinositol 3-kinase (PI3K)
complex, which includes the lipid kinase VPS34 and scaffolding subunits VPS15, Beclin1 and ATG14, is responsible for nucleation of the autophagophore (Mizushima et al.,
2011). Phosphatidyl-3-phosphate (PI3P) binds to Atg2/Atg18 complex, ATG2A, ATG2B
and WIPI1-4 proteins, leading to the elongation of the autophagophore (Mizushima et al.,
2011). A group of ubiquitin binding enzymes, E1 enzyme (ATG7), E2 enzyme
(ATG10/ATG3), and E3 complex (ATG12, ATG5, & ATG16L1) are required for covalent
conjugation of Atg8/LC3/GABARAP family members, which results in the conjugation of
Atg8/LC3 to the head group of the lipid phosphatidylethanolamine (PE). This lipid
modification of LC3 is typically referred to as LC3-II, which represents the activated form
of LC3 (Ogmundsdottir et al., 2018). Recent studies have shown that autophagosomes
can be selectively formed around specific cargo (i.e. misfolded proteins, peroxisomes and
damaged organelle such as mitochondria) when triggered by the binding of cargo to
selective cargo receptor proteins, such as SQSTM1, NBR1, OPTN, TOLLIP, NDP52 and
TAXBP1. The cargo receptors simultaneously bind the cargo (usually via ubiquitin chains)
and the autophagophore through the LIR domain of Atg8/LC3 (Zaffagnini and Martens,
2016). (Figure 2)
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Mitophagy refers to a form of selective autophagy that targets damaged or
dysfunctional mitochondria for autophagic clearance (Chu, 2019; Lionaki et al., 2015). As
damaged mitochondria are highly toxic to cells, mitochondrial quality control in the form
of mitophagy is vital for cellular health. A major pathway for the initiation of mitophagy is
through the PINK1-Parkin pathway. In healthy mitochondria, PINK1 is translocated to
mitochondria through the TOM and TIM complexes, proteolytically processed, and rapidly
degraded (Lazarou et al., 2012), thereby keeping PINK1 levels in check. However, upon
oxidative damage and subsequent mitochondrial depolarization, PINK1 is no longer
imported into the inner membrane of mitochondria and accumulates on the mitochondrial
outer membrane (MOM). This then triggers PINK1-dependent recruitment and
phosphorylation of the E3 ligase Parkin, which mediates the polyubiquitination of proteins
on the outer membrane (Kane et al., 2014; Katsuragi et al., 2015; Matsumoto et al., 2011;
Padman et al., 2019), thereby leading to the formation of autophagosomes around the
target mitochondria and its clearance upon fusion with lysosomes.

P62/SQSTM1
P62/SQSTM1, hereafter referred to as p62, is a major selective autophagy cargo receptor.
In humans, the SQSTM1 gene coding for p62 is located on chromosome 5, contains 8
exons, and is expressed in all cell types and tissues (Sanchez-Martin and Komatsu, 2018).
P62 is a multi-domain protein, which contains a Phox1 and Bem1p (PB1) domain, a ZZtype zinc finger (ZZ) domain, two nuclear localization signals (NLS), a TRAF6 binding
domain (TB), a LC3 Interaction zone (LIR), a Keap1 interaction zone (KIR) and a ubiquitinrelated (UBA) domain (Katsuragi et al., 2015). Of these, the ability of p62 to function as a
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selective autophagy cargo receptor depends on three essential domains. The N-terminal
PB1 domain mediates the self-interaction of p62 allowing the formation of p62 helical
filaments arranged in a head to tail configuration (Ciuffa et al., 2015). These filaments
function as scaffolds for the binding to multiple LC3 through LIR domain, thereby allowing
the nucleation of the autophagosome membrane together with p62 (Katsuragi et al.,
2015). The cargo-bound p62 acts as an autophagy inducer through the interaction of p62
to the LIR domain of LC3; this results in enhanced synthesis of LC3 and its conversion to
LC3-II to promote autophagosome formation (Cha-Molstad et al., 2017). The UBA domain
of p62 mediates the binding to ubiquitinated cargo (Matsumoto et al., 2011), and such
binding is regulated by several processes. First, homodimerization of the UBA domain
precludes polyubiquitin binding and contributes to p62 puncta abundance (Isogai et al.,
2011; Long et al., 2010), as deletion of the UBA domain impairs both ubiquitin binding
and formation of p62 bodies even in the presence of the PB1 domain (Ciuffa et al., 2015;
Matsumoto et al., 2011). A second regulatory process via direct ubiquitination of the UBA
domain on K420 has also recently been shown to modulate binding to ubiquitinated cargo
(Lee et al., 2017; Peng et al., 2017). Finally, Ser403 phosphorylation within the UBA
domain destabilizes UBA homodimerization and liberates the UBA domain from dimeric
repression, thereby allowing the UBA domain to bind polyubiquitinated cargo (Katsuragi
et al., 2015).
Previous studies have shown that p62 targets misfolded tau for autophagic
clearance. Specifically, p62/SQSTM1 knockout mice display severe neurodegeneration
as well as hyperphosphorylated tau and neurofibrillary tangles (Ramesh Babu et al.,
2008), and p62 overexpression strongly reduces pathogenic tau in transfected cells and
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in vivo (Xu et al., 2019). It has been reported that the activating phosphorylation on
Ser403 of p62 is significantly reduced in brains of Alzheimer’s disease (AD) patients (Tanji
et al., 2014), suggesting a failure of p62 to clear substrates as part of the disease
mechanism. Ser403 phosphorylation of p62 is mediated by ULK1 (Unc-51 Like
Autophagy Activating Kinase 1), CK2 (Casein kinase 2) or TBK1 (TANK-binding kinase
1), which increases p62 affinity for polyubiquitinated substrates (Katsuragi et al., 2015;
Matsumoto et al., 2015; Sanchez-Martin and Komatsu, 2018) and activates the
recruitment of LC3 (Jiang and Mizushima, 2015; Katsuragi et al., 2015). This
phosphorylation is transient and subject to rapid dephosphorylation (Matsumoto et al.,
2015). However, to date, the identity of phosphatases that physiologically mediate p62
dephosphorylation on pSer403 has remained mysterious.

Slingshot Homolog 1 and Cofilin
Slingshot (SSH) was originally identified in Drosophila. Loss of SSH function in Drosophila
leads to morphological disorder of epidermal cells, including bristles, wing hairs and germ
malformations (Ohashi, 2015). Therefore, SSH participates in the formation of cell
expansion by organizing the ordered assembly of Drosophila actin filaments. In mammals,
Slingshot Homolog-1 (SSH1) is recognized as the major phosphatase that activates the
F-actin-severing protein cofilin on pSer3 (Niwa et al., 2002). Cofilin, a family of actinbinding protein, is one of the key regulators of actin dynamics via its F-Actin severing,
depolymerizing, nucleating, and bundling activities (Bamburg and Bernstein, 2016).
Cofilin is inactivated by phosphorylation on Ser3 by LIM kinase1 (LIMK1) (Arber et al.,
1998), whereas its dephosphorylation by SSH1 activates cofilin (Niwa et al., 2002).
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Activated cofilin differentially modulates actin dynamics depending on the ratio of cofilin
to actin. At regions of high cofilin/actin ratios, cofilin can bind and stabilize F-actin in a
twisted form, thereby promoting the nucleation of actin rather than severing
(Andrianantoandro and Pollard, 2006). However, at regions of low cofilin/actin ratios,
cofilin does not bind ADP-actin fast enough to saturate F-actin but induces persistent
severing to create new barbed and pointed ends (Andrianantoandro and Pollard, 2006).
Multiple studies have implicated the involvement of activated cofilin in amyloid β
(Aβ)-induced dendritic spine shrinkage (Shankar et al., 2007; Zhao et al., 2006),
accumulation of cofilin-actin aggregates/rods in AD brains (Minamide et al., 2000;
Rahman et al., 2014), and increased cofilin activity in brains of AD patients (Kim et al.,
2013; Zhao et al., 2006) and AD mouse models (Woo, 2015). Activated cofilin also plays
an important role in mitochondrial dysfunction via direct translocation to mitochondria
(Chua et al., 2003; Klamt et al., 2009; Wang et al., 2008). Woo and colleagues first
demonstrated that Aβ1-42 oligomers promote the translocation of cofilin to mitochondria,
which induces a drop in mitochondrial membrane potential, increase in mitochondrial
superoxide, and cell death. These events are largely abolished by siRNA-mediated
knockdown of cofilin (Woo et al., 2012) or SSH1 (Woo et al., 2015a). In brains of AD
patients, the level of mitochondrial cofilin is strongly increased compared to healthy agematched controls (Woo et al., 2015a), indicating a role for cofilin in mitochondrial
dysfunction in AD. Moreover, SSH1-cofilin protein complexes are significantly increased
in APP/PS1 transgenic mice, consistent with increased activation of cofilin (Woo et al.,
2015a). Finally, Woo and colleagues recently reported that cofilin reduction mitigates
tauopathy in tauP301S mice through reduced displacement of tau from microtubules, as
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activated / dephosphorylated cofilin promotes tau detachment from microtubules;
however, activated cofilin per se does not directly regulate tau levels (Woo et al., 2019).
(Figure 3)
In this study, we report the identification of SSH1 as the first phosphatase that
dephosphorylates p62 on pSer403, resulting in significant physiological and pathological
consequences. This function of SSH1 on p62, which is modular and separable from its
activity on cofilin, impairs p62-mediated selective autophagy, thereby impeding the
clearance of damaged mitochondria and phospho-tau. (Figure 4)

19

Figure 1. Schematic model of the effect of amyloid-β (Aβ) and phosphorylated-Tau
(pTau) (Garcia-Escudero et al., 2013). Scheme of the effect of amyloid-β (Aβ) and
phosphorylated-Tau (pTau) over mitochondrial dynamics, transport, protein import, membrane
permeabilization, and apoptosis as well as actin dynamics. Alterations of the levels of involved
proteins found in AD brains are also summarized. DLP1: dynamin-like protein 1, MFF:
mitochondrial fission factor, FIS: fission 1, MIEF: mitochondrial elongation factor, MFN1: mitofusin
1, MFN2: mitofusin 2, OPA1: optic atrophy 1, PHB1: prohibitin 1, ABAD: Aβ-binding alcohol
dehydrogenase, Prep: presequence protease, VDAC: voltage-dependent anion channel, ANT:
adenine nucleotide translocase, CypD: cyclophilin D, Cyt C: cytochrome c, COX: cytochrome c
oxidase, Ψm: mitochondrial membrane potential, and mtDNA: mitochondrial DNA (GarciaEscudero et al., 2013).
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Figure 2. Schematic model of autophagy and mitophagy (Kaur and Debnath, 2015).
a. Initiation begins with the formation of the phagophore assembly site (PAS). This is mediated
by the UNC51-like kinase (ULK) complex, which consists of ULK1 (or ULK2), autophagy-related
protein 13 (ATG13), FAK family kinase interacting protein of 200 kDa (FIP200) and ATG101.
Further nucleation requires the class III PI3K complex, which is composed of the vacuolar protein
sorting 34 (VPS34) PI3K, along with its regulatory subunits ATG14L, VPS15 and beclin 1 (Atg6
in yeast). Phagophore membrane elongation and autophagosome completion requires two
ubiquitin-like conjugation pathways. The first produces the ATG5–ATG12 conjugate, which forms
a multimeric complex with ATG16L, whereas the second results in the conjugation of
phosphatidylethanolamine (PE) to LC3 (Atg8 in yeast). PE-conjugated LC3 (LC3–PE) is required
for the expansion of autophagic membranes, their ability to recognize autophagic cargoes and
the fusion of autophagosomes with lysosomes. Autophagosome fusion with lysosomal leading to
formation of the autolysosome. In microautophagy, substrates are directly engulfed at the
boundary of the lysosomal membrane. In chaperone-mediated autophagy, substrates with the
pentapeptide motif KFERQ are selectively recognized by the heat shock cognate 70 kDa protein
(HSC70) chaperone and translocated to lysosomes in a LAMP2A-dependent manner. In all three
processes, the autophagic cargo is degraded via lysosomal hydrolases. b. The selective
autophagy of proteins and organelles is mediated by autophagy cargo receptors, which interact
with both the autophagic substrate and the developing autophagosome via an LC3-interacting
region (LIR). BAG3, BAG family molecular chaperone regulator 3; BNIP3, BCL2/adenovirus E1B
19 kDa protein-interacting protein 3; FUNDC1, FUN14 domain-containing protein 1; HDAC6,
histone deactylase 6; NBR1, next to BRCA1 gene 1 protein; NIX, NIP3-like protein X; OPTN,
optineurin; Ub, ubiquitin.(Kaur and Debnath, 2015)

21

Figure 3. Schematic of activated cofilin in Alzheimer’s disease and other
tauopathies (Woo et al., 2019). Under pathological conditions (i.e. Aβ and/or oxidative stress)
oxidation of 14-3-3 releases SSH1, thereby allowing cofilin activation by dephosphorylation.
Activated cofilin not only deregulates F-actin dynamics (severing and cofilin–actin aggregation)
and promotes mitochondrial dysfunction but also directly competes with tau for binding to
microtubules. This results in displacement of tau from microtubules, destabilization of
microtubules, and promotion of tauopathy (Woo et al., 2019).
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Figure 4. Schematic model of SSH1 in p62-mediated selective autophagy. In healthy
neurons, regulated activation of p62 by phosphorylation on Ser403 by ULK, TBK1, or CK2
promotes LC3 activation and p62 binding to ubiquitinated misfolded proteins (i.e. phospho-tau)
and damaged organelle (i.e. mitochondria), leading to normal clearance through the autophagylysosome system. Deactivation of p62 by SSH1-mediated dephosphorylation of Ser403 renders
p62 unable to activate LC3 and bind to ubiquitinated cargo, leading to their accumulation and
toxicity.
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CHAPTER 2

SSH1 IMPAIRS MITOPHAGY INDUCTION AND LC3 BIOGENESIS
WITHOUT ALTERING LC3 FLUX

SSH1 impairs LC3 recruitment to mitochondria and impedes mitophagy
We previously showed that SSH1 reduction prevents Aβ42 oligomers (Aβ42O)-induced
translocation of cofilin to mitochondria, mitochondrial dysfunction, and toxicity (Roh et al.,
2013; Woo et al., 2012; Woo, 2015). As damaged mitochondria are targeted for clearance
by mitophagy, we looked for evidence of mitophagy in hippocampus derived HT22
neuroblastoma cells treated with Aβ42O. LC3 is a central protein in autophagy where it
functions in autophagosome biogenesis and hence is used as an autophagosome marker
(Jiang and Mizushima, 2015). Aβ42O treatment (1µM) weakly increased the number of
endogenous LC3 puncta and their association with mitochondria (Tom20) at 8h (Fig. 1AC), indicative of mild mitophagy induction. However, both LC3 puncta and their
association with mitochondria gradually subsided below control levels after 24-48h (Fig.
5 A, B). In contrast, RNAi-mediated knockdown of SSH1 increased the number of
endogenous LC3 puncta and their association with mitochondria at steady state, both of
which were further increased at 8h and remained highly elevated for up to 48h post Aβ42O
treatment (Fig. 5 A-C). Knockdown of SSH1 by siRNA was confirmed by
immunocytochemical staining for SSH1 (Fig. 5 A) and Western blotting (Fig. 5 D). To
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confirm this finding in a different way, we transfected HT22 cells with vector control or
SSH1-Flag together with RFP-LC3 to directly visualize LC3. We then depolarized
mitochondria with the mitochondrial uncoupler FCCP for up to 4h and assayed for total
RFP-LC3 puncta and colocalization with mitochondria (Tom20). As expected, FCCP
treatment increased the number of RFP-LC3 puncta outside the nucleus (Fig. 5 E, F1),
indicative of induced autophagosome formation; this was proportionately reflected in
increased RFP-LC3 colocalized with Tom20+ mitochondria (Fig. 5 E, F2). SSH1
overexpression significantly reduced the number of RFP-LC3 puncta at steady state and
after FCCP treatment (Fig. 5 E, F1), which was reflected in proportionately decreased
RFP-LC3 puncta associated with Tom20+ mitochondria (Fig. 5 E, F2). As the reduction
of LC3 recruited to mitochondria is expected to impair mitochondrial clearance, we
assessed mitophagy using the mito-keima flux reporter, in which 458/561nm dual
excitation and 620nm emission produces a measure of mitophagy flux (Sun et al., 2015).
Indeed, we confirmed that SSH1 overexpression significantly impedes FCCP-induced
mitophagy flux (Fig. 6 A, C), whereas SSH1 siRNA significantly accelerates FCCPinduced mitophagy flux over a 2h period (Fig. 6 B, D).

SSH1 suppresses LC3-II biogenesis but does not alter LC3 flux
LC3-II is the active lipid modified form of LC3 involved in autophagosome membrane
expansion and fusion (Khaminets et al., 2016; Weidberg et al., 2011). As SSH1
overexpression significantly reduced the number of LC3 puncta, we tested if SSH1 alters
LC3-II levels. SSH1 overexpression significantly reduced LC3-II at steady state (Fig. 7 A,
B). FCCP treatment for 4h increased LC3-II levels as expected, and SSH1
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overexpression also significantly suppressed FCCP-induced LC3-II generation (Fig.7 A,
C). The reduction in LC3-II may be due to reduced biogenesis from LC3-I or accelerated
clearance by the lysosome. To determine if the reduction in LC3-II by SSH1 is due
accelerated lysosomal clearance, we treated HT22 cells with FCCP (4h) or rapamycin
(16h) with or without the lysosome inhibitor bafilomycin A (final 4h). FCCP markedly
increased LC3-II after 4h but did not further increase with bafilomycin co-treatment,
suggesting that FCCP-induced LC3-II generation is far greater than its turnover during
this time period (Fig. 8 A, C). SSH1 transfection significantly reduced FCCP-induced LC3II both in the presence and absence of bafilomycin A (Fig. 8 A, C). Rapamycin treatment
over 16h did not show a substantial increase LC3-II; however, co-treatment of rapamycin
with bafilomycin during the final 4h dramatically increased LC3-II in control transfected
cells (Fig. 8 B, D), indicating rapamycin-induced LC3-II flux and clearance by the
lysosome. This bafilomycin-induced accumulation of LC3-II was significantly blunted in
SSH1 transfected cells (Fig. 8 B, D). Hence, these results indicate that SSH1 suppresses
LC3-II biogenesis at a step prior to flux to lysosomes.
To assess the effects of SSH1 on LC3 in a dynamic way, we used the mCherryGFP-LC3 flux reporter construct. This reporter takes advantage of GFP’s sensitivity to
low pH (quenching), mCherry’s insensitivity to low pH, and LC3, which allows the tracking
of LC3 to lysosomes (Kimura et al., 2007; Nyfeler et al., 2012; Pankiv et al., 2007).
Therefore, perfectly colocalized red and green puncta (yellow) are indicative of nonlysosomal LC3. However, upon fusion with lysosomes (autolysosomes), red puncta
persist while green puncta disappear (red-only). HT22 cells were co-transfected with
mCherry-GFP-LC3 with vector control or SSH1-Flag and treated with or without FCCP
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for up to 4h. As expected, FCCP increased the total number of LC3 puncta (Fig. 8 E, F)
and red-only puncta (Fig. 8 E, G) in a time-dependent manner in control vector transfected
cells. SSH1 overexpression significantly reduced the total number of total LC3 puncta
(Fig. 8 E, F) and red-only LC3 puncta (Fig. 8 E, G). However, the percentage of red-only
puncta was not significantly altered by SSH1 overexpression (Fig. 8 H), indicating that
SSH1 does not alter LC3 flux to lysosomes. Bafilomycin A treatment similarly increased
the total number of LC3 puncta in control and SSH1 transfected cells (Fig. 7 D, E),
confirming that SSH1 does not alter lysosomal LC3 clearance.

Figure 5 A-D. SSH1 impairs LC3 recruitment to mitochondria and impedes
mitophagy flux
A. Representative images from the 8h Aβ42 oligomer treatment condition with white insets
magnified. HT22 cells transfected with control siRNA or SSH1 siRNA, treated with Aβ42 oligomers
(1µM) for 48h, 36h, 24h, 8h, or 0h (DMSO), and subjected to staining for SSH1 (dark blue), LC3
(red), Tom20 (green), and DAPI (light blue).
B, C. Quantitative graphs of figure A expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n>10/condition from 3 different experiments, *p<0.05, **p<0.005, ***p<0.0005,
#p<0.0001.
D. Representative blots showing knockdown of SSH1 by siRNA.
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Figure 5 E-F. SSH1 impairs LC3 recruitment to mitochondria and impedes
mitophagy flux
E. Representative images from the 4h FCCP treatment condition with white insets magnified.
HT22 cells co-transfected with RFP-LC3 and vector control (p3xFlag) or Flag-SSH1, treated with
5µM FCCP for 4h, 2h, 0.5h, or 0h (DMSO), and stained for Flag (light blue) and Tom20 (green)
or directly imaged for RFP-LC3 (red).
F. Quantitative graphs of figure E expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n>20/condition from 3 different experiments, *p<0.05, ***p<0.0005, #p<0.0001.

28

Figure 6. SSH1 impairs LC3 recruitment to mitochondria and impedes mitophagy
flux
A. Representative images from HT22 cells co-transfected with mito-keima and vector control or
Flag-SSH1, treated with 5µM FCCP for 2h, 1h, and 0h (DMSO), and subjected to live cell imaging
for mito-keima by dual excitation at 458nm/561nm and imaging at 620nm. 458 excitation images
pseudo-colored to green.
B. Representative images from HT22 cells co-transfected with mito-keima and control siRNA or
SSH1 siRNA, treated with 5µM FCCP for 2h, 1h, and 0h (DMSO), and subjected to live cell
imaging for mito-keima by dual excitation at 458nm/561nm and imaging at 620nm. 458 excitation
images pseudo-colored to green.
C. Quantitative graph of figure A expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=5/condition, #p<0.0001.
D. Quantitative graph of figure B expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=5/condition, #p<0.0001.
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Figure 7. SSH1 suppresses LC3-II biogenesis but does not alter LC3 flux
A. Representative blots of LC3, SSH1, and Actin from HT22 cells co-transfected vector control
(p3xFlag) or Flag-SSH1, treated with 5µM FCCP for 4h or 0h (DMSO). Two different exposures
shown for the LC3 blot.
B-C. Quantitative graphs of figure A expressed as means ± SEM, t-test, **p<0.005, #p<0.0001.
D. Representative images from HT22 cells co-transfected with mCherry-GFP-LC3 and vector
control (p3xFlag) or Flag-SSH1, treated with DMSO or 200nM bafilomycin for 2h, and subjected
to staining for Flag-M2 (light blue) and direct imaging for mCherry-GFP-LC3 (red & green).
E. Quantitative graph of figure D expressed as mean ± SEM, two-way ANOVA with Tukey's
posthoc test, n=15/condition from 3 different experiments, **p<0.005.
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Figure 8 A-D. SSH1 suppresses LC3-II biogenesis but does not alter LC3 flux
A. Representative blots from HT22 cells transfected with vector control or Flag-SSH1, treated +
5µM FCCP + 200nM bafilomycin A for 4h, and subjected to Western blotting for LC3, SSH1, and
Actin.
B. Representative blots from HT22 cells transfected with vector control or Flag-SSH1, treated +
200nM rapamycin for 16h + 200nM bafilomycin A for 4h, and subjected to Western blotting for
LC3, SSH1, and Actin.
C. Quantitative graph of figure A expressed as means ± SEM, two-way ANOVA with Sidak’s
posthoc test, n=4/condition, *p<0.05, #p<0.0001.
D. Quantitative graph of figure B expressed as mean ± SEM, two-way ANOVA with Sidak’s
posthoc test, n=4/condition, *p<0.05, #p<0.0001.
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Figure 8 E-H. SSH1 suppresses LC3-II biogenesis but does not alter LC3 flux
E. Representative images at 4h FCCP condition with white insets magnified. HT22 cells cotransfected with mCherry-GFP-LC3 and vector control (p3xFlag) or Flag-SSH1, treated with 5µM
FCCP for 4h, 2h, 0.5h, or 0h (DMSO), and subjected to staining for Flag-M2 (light blue) and direct
fluorescence imaging (mCherry: red, GFP: green).
F-H. Quantitative graphs of figure E expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n>15/condition from 3 different experiments, *p<0.05, **p<0.005, #p<0.0001.
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CHAPTER 3

SSH1 IMPAIRS MITOPHAGY INDUCTION AND LC3 BIOGENESIS VIA INHIBITION
OF P62 SER403 PHOSPHORYLATION AND P62-UBIQUITIN BINDING

SSH1-mediated inhibition of p62 flux underlies LC3 suppression
The observation that SSH1 significantly inhibits LC3-II generation and LC3 puncta
formation while having no effects on LC3 flux led us to hypothesize that such SSH1mediated effects originate upstream of LC3. The autophagosome protein LC3 binds to
autophagy cargo receptors, such as p62 and optineurin. These cargo receptors recognize
polyubiquitinated cargo via the UBA domain and recruit LC3 through the LIR domain
(Katsuragi et al., 2015). Interestingly, a recent study showed that the cargo-bound p62
also acts as an autophagy inducer, enhancing the synthesis of LC3 and its conversion to
LC3-II to promote autophagosome formation (Cha-Molstad et al., 2017). Hence, we
initially co-transfected HT22 cells with GFP-p62 or GFP-optineurin with vector control or
SSH1-Flag. Neither total GFP-optineurin puncta number nor its recruitment to Tom20+
mitochondria was altered by SSH1 transfection at steady state or after FCCP treatment
(Supplemental Fig. S1 A-C). However, SSH1 overexpression significantly reduced the
total number of GFP-p62 puncta and decreased GFP-p62 recruited to Tom20+
mitochondria at steady state and after FCCP (Supplemental Fig. S1 D-F). To investigate
SSH1-induced changes in p62 further, we assessed p62 flux using the mCherry-GFP-
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p62 reporter (Larsen et al., 2010; Li et al., 2014; Pankiv et al., 2007), which allows tracking
of p62 puncta flux according to the same principle as mCherry-GFP-LC3. In vector control
transfected HT22 cells, FCCP treatment generally increased total p62 puncta and redonly acidified p62 puncta (Fig. 9 A-C). However, SSH1 significantly reduced total p62
puncta and even more robustly reduced red-only p62 puncta even with FCCP treatment
(Fig. 9 A-C). Hence, SSH1 significantly reduced the percentage of red-only p62 puncta
compared to vector control (Fig. 9 A, D), indicating that SSH1 impedes p62 flux. SSH1
siRNA transfection, in contrast, significantly increased the number of p62 puncta and
those that were recruited to Tom20+ mitochondria in the absence and presence of FCCP
(Supplemental Fig. S1 G-I), indicating that endogenous SSH1 normally inhibits p62
function. To determine if p62 is required for the effects of SSH1 on LC3, we co-transfected
control or p62 siRNA together with control or SSH1 siRNA. As expected, p62 siRNA
greatly reduced the number of endogenous LC3 puncta (Fig. 9 E, F) and their recruitment
to mitochondria (Fig. 9 E, G, H), while SSH1 siRNA dramatically increased total LC3
puncta (Fig. 9 E, F) and their recruitment to mitochondria (Fig. 9 E, G, H). However, SSH1
siRNA failed to increase LC3 puncta or recruitment to mitochondria when p62 was
knocked down (Fig. 9 E-H), indicating that the inhibitory effects of SSH1 on LC3 require
endogenous p62.

SSH1 decreases p62 Ser403 phosphorylation and inhibits p62-ubiquitin binding
The activity of p62 is positively regulated by its phosphorylation on Ser403 within the Cterminal ubiquitin-associated (UBA) domain by TBK1, ULK, or CK2 (Katsuragi et al., 2015;
Matsumoto et al., 2015; Sanchez-Martin and Komatsu, 2018).This phosphorylation is
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known to activate p62 and increase p62 affinity for polyubiquitin chains, thereby
enhancing its ability to recognize misfolded proteins or dysfunctional mitochondria tagged
for clearance (Matsumoto et al., 2011). Importantly, the ratio of soluble Ser403phosphorylated p62 (pS403-p62) to total p62 is significantly reduced in brains of AD
patients (Tanji et al., 2014). As SSH1 is a phosphatase, we hypothesized that the
inhibitory action of SSH1 on p62 might be associated with p62 dephosphorylation on
Ser403. Overexpression of SSH1-Flag in HT22 cells resulted in significantly reduced
endogenous pS403-p62 without altering total p62 (Fig. 10 A, B). Conversely, siRNA
knockdown of SSH1 significantly increased endogenous pS403-p62 without altering total
p62 (Fig. 10 C, D).
To determine if SSH1-mediated reduction in pS403-p62 alters p62 binding to
ubiquitin, we assessed p62-ubiquitin complexes in 3 ways. First, we co-transfected HT22
cells

with

HA-ubiquitin,

GFP-p62,

and/or

SSH1-Flag,

and

performed

co-

immunoprecipitation (co-IP) experiments to assess p62-ubiquitin complexes. Co-IP
studies confirmed that SSH1 transfected cells contain significantly reduced GFP-p62 in
HA-ubiquitin immune complexes (Fig. 10 E1, E3), despite equivalent levels of HAubiquitin, GFP-p62, and SSH1-Flag expression (Fig. 10 E1, E2). Second, we detected
the colocalization of ubiquitin with p62 puncta by immunocytochemistry (ICC) from HT22
cells co-transfected with GFP-p62 and HA-ubiquitin with/without SSH1-Flag. By Manders
split colocalization assessment, we found significantly reduced number of GFP-p62
puncta (Fig. 10 F, G), number of GFP-p62 puncta colocalized with HA-ubiquitin (Fig. 10
F, H), and percentage of GFP-p62 puncta colocalized with HA-ubiquitin (Fig. 10 F, I) in
SSH1-Flag transfected cells in the presence or absence of FCCP treatment. Third, we
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detected p62-ubiqutin complexes by Duolink® in situ proximity ligation assays (PLA)
(Millipore Sigma), a powerful tool that allows in situ detection of protein-protein
interactions with high specificity and sensitivity. In PLA, two antibodies (raised against
different species) for corresponding proteins are applied, after which a pair of
oligonucleotide-labeled secondary antibodies bind to primary antibodies. If in close
proximity to each other (~40 angstroms) (Fredriksson et al., 2002), connector oligos join
the PLA probes and are ligated to form circular DNA that are amplified by DNA
polymerase. This allows up to 1000-fold amplification, and complementary detection
oligos coupled to a fluorochrome are hybridized to detect the PLA signal. Using PLA and
two antibodies directed against p62 and ubiquitin, we detected endogenous p62-ubiqutin
complexes, which were significantly reduced by ~70% in SSH1 transfected cells (Fig. 10
J, K; red PLA puncta). Exclusion of 1 primary or 1 secondary antibody yielded no
detectable PLA signal, indicating specificity of the assay (Supplemental Fig. S2).
Therefore, these data collectively show that SSH1 reduces p62 phosphorylation on
Ser403, which inhibits p62 binding to ubiquitinated substrates and downstream LC3
activation.

SSH1-mediated p62 inhibition requires pSer403 modification of p62
The C-terminal region of p62 contains the LC3-interacting LIR domain and the ubiquitininteracting UBA domain (Supplemental Fig. S3 A). To determine if these regions of p62
are required for the inhibitory effects of SSH1, we co-transfected the GFP-p62ΔC (lacking
both LIR and UBA domains) with vector control or SSH1-Flag. SSH1 had no significant
inhibitory effect on the number of GFP-p62ΔC puncta with or without FCCP treatment
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(Supplementary Fig. S3 B, C), indicating that the C-terminal region is required for the
SSH1-induced inhibition of p62. Next, we used the GFP-p62-LIR mutant, in which the
LC3-binding site in the LIR domain of p62 has been mutated to prevent LC3 binding
(Itakura and Mizushima, 2011) (Supplemental Fig. S3 A). In contrast to the GFP-p62ΔC
mutant, SSH1 overexpression significantly reduced the number of GFP-p62-LIR puncta
and

number of

GFP-p62-LIR puncta colocalized

with

Tom20+ mitochondria

(Supplemental Fig. S3 D-F), indicating that p62-LC3 binding per se is not required for the
inhibitory effect of SSH1 on p62. The N-terminal PB1 domain is required for initial p62
self-interaction to allow the formation of p62 helical filaments arranged in a head to tail
configuration (Ciuffa et al., 2015). Because SSH1 reduced the number of p62 puncta, we
assessed whether SSH1 inhibits p62 self-interaction at the molecular level. However, we
found no evidence that SSH1 affects p62 self-interaction by co-IP (Supplemental Fig. S3
G) or PLA (Supplemental Fig. S3 H, I) experiments, suggesting that SSH1 does not
directly alter the PB1 self-interaction domain.
To determine if the inhibitory actions of SSH1 on p62 depend on the UBA domain
Ser403 phosphorylation status, we generated 2 artificial p62 constructs: GFP-p62-S403A
and GFP-p62-S403E, the former that cannot be phosphorylated and the latter that mimics
phosphorylation on Ser403 (Supplemental Fig. S3 A). The p62-S403E mutant has been
shown to increase p62 binding affinity for ubiquitin, resulting in efficient targeting of
polyubiquitinated substrates in sequestosomes for autophagosome entry (Matsumoto et
al., 2011). Upon expression of these constructs in HT22 cells, we observed a significant
~65% increase in the number of GFP-p62-S403E puncta compared to equivalent
transfection of GFP-p62-S403A at steady state (Fig. 11 A, B). Manders split colocalization
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with Tom20+ mitochondria demonstrated an even more significant ~3-fold increase in
GFP-p62-S403E recruitment to mitochondria compared to GFP-p62-S403A (Fig. 11 A,
B), indicating that Ser403 ‘phosphorylated’ p62 is indeed more active in enhancing puncta
number and recruitment to mitochondria. FCCP treatment (4h) further significantly
increased the number of total GFP-p62-S403E puncta and association with mitochondria
compared to GFP-p62-S403A (Fig. 11 A, B). GFP-p62-S403A was completely
unresponsive to FCCP in both measures (Fig. 11 B), indicating that mitochondrial
depolarization recruits only Ser403-phosphorylated p62. Overexpression of SSH1-flag
had no effect on either GFP-p62-S403E or GFP-p62-S403A on the number of p62 puncta
or their recruitment to mitochondria in the absence or presence FCCP (Fig. 11 A, C, D).
Likewise, siRNA-mediated knockdown of SSH1 had no significant effect on either GFPp62-S403E or GFP-p62-S403A on the number of puncta or recruitment to mitochondria
in the absence or presence FCCP (Supplemental Fig. S 11 J-O), collectively
demonstrating that the inhibitory action of SSH1 on p62 requires p62 modification on
Ser403.
Ser403 phosphorylation of p62 has been shown to inhibit the dimerization of the
UBA domain independent of the PB1 domain (Ciuffa et al., 2015). Hence, we set out to
measure the sizes of mutant GFP-p62-S403A/E puncta. Due to the wide range of puncta
sizes, we first assessed puncta size by 4 increasing size categories. The S403A mutant
significantly increased the distribution of puncta to the 2 largest size categories (>5µm2 &
1-5µm2) compared to the S403E mutant (Fig. 11 E), and the average size of S403A
puncta in these categories were significantly larger than S403E puncta (Fig. 11 F). We
also assessed wild type GFP-p62 puncta sizes with or without SSH1-Flag transfection.
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Like the S403A mutation, SSH1 significantly increased the distribution of GFP-p62 puncta
to the 2 largest size categories compared to vector control (Fig. 11 G, H), and SSH1
transfected cells contained significantly larger GFP-p62 puncta compared to vector
control in these size categories (Fig. 11 I). As expected, SSH1 also significantly reduced
the total number of GFP-p62 puncta and those colocalized with Tom20+ mitochondria
(Supplemental Fig. S3 P, Q). These data therefore demonstrate that SSH1-mediated
reduction in pSer403 phosphorylation recapitulates the S403A mutation in all measures
and suggest that loss of pSer403 phosphorylation decreases p62 puncta number by
coalescing smaller puncta into larger puncta.

Figure 9 A. SSH1-mediated inhibition of p62 underlies LC3 suppression
A. Representative images at 4h FCCP condition with white insets magnified. HT22 cells cotransfected with mCherry-GFP-p62 and control (p3xFlag) or Flag-SSH1, treated with 5µM FCCP
for 4h, 2h, 0.5h, or 0h (DMSO), and subjected to staining for Flag-M2 (dark blue) or direct imaging
(mCherry: red, GFP: green).
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Figure 9 B-D. SSH1-mediated inhibition of p62 underlies LC3 suppression
B-D. Quantitative graphs of figure A expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n>15/condition from 3 different experiments, *p<0.05, **p<0.005, ***p<0.0005,
#p<0.0001.
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Figure 9 E-H. SSH1-mediated inhibition of p62 underlies LC3 suppression
E. Representative images at 4h FCCP condition with white insets magnified. HT22 cells
transfected with control siRNA, SSH1 siRNA, p62 siRNA or both SSH1 and p62 siRNA, treated
with 5µM FCCP for 4h, 2h, 0.5h, or 1h (DMSO), incubated with MitoTracker-Green for 45min
before fixation, and subjected to staining for LC3 (red), p62 (light blue), and SSH1 (dark blue) or
direct imaging (LC3: red).
F-H. Quantitative graphs of figure E expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n>20/condition from 3 different experiments, *p<0.05, **p<0.005, #p<0.0001.
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Figure 10 A-E. SSH1 decreases p62 Ser403 phosphorylation and inhibits p62ubiquitin binding
A. Representative blots of pS403 p62 from HT22 cells transfected with vector control (p3xFlag)
or Flag-SSH1.
B. Quantitative graph of figure A expressed as means ± SEM, t-test, n=4/condition, *p<0.05.
C. Representative blots of pS403 p62 from HT22 cells transfected with control siRNA or SSH1siRNA.
D. Quantitative graph of figure C expressed as means ± SEM, t-test, n=4/condition *p<0.05.
E1-E3. Representative blots showing co-immunoprecipitation of HA-ubiquitin and GFP-p62 in
HT22 cells transfected with control (p3xFlag) or Flag-SSH1. Figure E3 shows quantitative graph
of figure E1 (p62-ubiqutin co-IP) expressed as means ± SEM, t-test, n=4, *p<0.05.
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Figure 10 F-I. SSH1 decreases p62 Ser403 phosphorylation and inhibits p62ubiquitin binding
F. Representative images at 4h FCCP condition with white insets magnified. HT22 cells cotransfected with GFP-p62 and vector control (p3xFlag) or Flag-SSH1, treated with 5µM FCCP for
4h, 0.5h, or 0h (DMSO), and subjected to staining for Flag-M2 (light blue), p62 (green), and
ubiquitin (red).
G-I. Quantitative graphs of figure F expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n>20/condition from 3 different experiments, *p<0.05, #p<0.0001.
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Figure 10 J-K. SSH1 decreases p62 Ser403 phosphorylation and inhibits p62ubiquitin binding
J. Representative images with white insets magnified. HT22 cells transfected with control (GFP)
or GFP-SSH1 and subjected to in situ PLA for p62-ubiqutin complexes (red) or direct imaging
(GFP: green).
K. Quantitative graph of figure J expressed as means ± SEM, t-test, n>18/condition from 3
different experiments, #p<0.aa0001.
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Figure 11 A. SSH1-mediated p62 inhibition requires pSer403 modification of p62
A. Representative images at 4h FCCP condition with white insets magnified. HT22 cells cotransfected with GFP-p62-S403E or GFP-p62-S403A and mito-dsRed + vector control or FlagSSH1, treated with 5µM FCCP for 4h or 0h (DMSO), and subjected to staining for Flag-M2 (dark
blue) and DAPI (light blue) or direct imaging (mito-dsRed; red, GFP-p62: green).
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Figure 11 B-F. SSH1-mediated p62 inhibition requires pSer403 modification of p62
B-D. Quantitative graphs of figure A expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n>15/condition from 3 different experiments, *p<0.05, **p<0.005, ***p<0.0005,
#p<0.0001.
E. Quantitative graphs of figure A showing the distribution of p62 puncta number across size
categories, 2 test for trend, n>15/condition from 3 different experiments, p=0.0019 (FCCP 0h),
p=0.0015 (FCCP 4h).
F. Quantitative graphs of figure A expressed as means ± SEM in different size categories, twoway ANOVA with Tukey's posthoc test, n>15/condition from 3 different experiments, *p<0.05,
**p<0.005.
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Figure 11 G-I. SSH1-mediated p62 inhibition requires pSer403 modification of p62
G. Representative images at 4h FCCP condition with white insets magnified. HT22 cells cotransfected with GFP-p62-WT, mito-dsRed, and vector control (p3xFlag) or Flag-SSH1, treated
with 5µM FCCP for 4h or 0h (DMSO), and subjected to staining for Flag-M2 (dark blue) and DAPI
(light blue) or direct imaging (GFP-p62: green, mito-dsRed: red).
H. Quantitative graphs of figure G showing the distribution of p62 puncta number across size
categories, 2 test for trend, n>15/condition from 3 different experiments, p<0.0001 (FCCP 0h),
p=0.0021 (FCCP 4h).
I. Quantitative graphs of figure G expressed as mean ± SEM in different size categories, two-way
ANOVA with Tukey's posthoc test, n>15/condition from 3 different experiments, *p<0.05,
***p<0.0005.
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CHAPTER 4

DEPHOSPHORYLATION OF P62 BY SSH1 IS INDEPENDENT FROM
DEPHOSPHORYLATION OF COFILIN

SSH1ΔN dephosphorylates pSer403-p62 but not pSer3-cofilin and inhibits p62
activity
SSH1 contains an N-terminal phospho-cofilin binding site (pCof) within the N-terminal
region, followed by the catalytic domain (CAT) and a sizable C-terminal region of
unknown function (Fig. 12 A) (Kurita et al., 2008). It has been shown that SSH1ΔC (or
N461), containing the N-terminal 461 residues but lacking C-terminal residues 462-1049,
is sufficient to dephosphorylate cofilin on Ser3 (pS3-cofilin), whereas the C393S mutation
in the catalytic site destroys SSH1 phosphatase activity (Kurita et al., 2008). To determine
which domains of SSH1 are required for pSer403 p62 dephosphorylation, we obtained
the SSH1ΔC construct (Kurita et al., 2008) and generated the SSH1ΔN and SSH1ΔNC393S constructs lacking the N-terminal 307 amino acids (phospho-cofilin binding region)
but containing the catalytic domain and the C-terminal region (Fig. 12 A). As expected,
overexpression of SSH1ΔC robustly reduced pSer3-cofilin (Fig. 12 B); however, SSH1ΔC
failed to alter pS403-p62 (Fig. 12 B, C). In contrast, neither SSH1ΔN nor SSH1ΔN-C393S
altered pSer3-cofilin (Fig. 12 B), and SSH1ΔN but not SSH1ΔN-C393S strongly reduced
pSer403-p62 (Fig. 12 B,C). To determine if SSH1 can directly dephosphorylate pSer403-
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p62, we expressed and purified SSH1ΔC-His, SSH1ΔN-His, and p62-His produced in Sf9
insect cells. In Sf9 cells, purified recombinant p62-His contained Ser403 phosphorylation
(Fig. 12 D). Co-incubation of recombinant p62-His with SSH1 variants for 0.5h and 2h
conclusively showed that SSH1ΔN but not SSH1ΔC directly dephosphorylates pSer403p62 (Fig. 12 D). In HEK293T cells co-transfected with HA-p62 with/without SSH1-Flag or
SSH1 N-Flag, both SSH1 variants similarly co-immunoprecipitated with HA-p62,
whereas little to no SSH1ΔN-Flag was present when no HA-p62 was transfected or pulled
down with IgG beads alone (Supplemental Fig. S4 A, B).
To test whether SSH1ΔN and SSH1ΔC differentially alters p62 activity, we cotransfected SSH1ΔC-Flag or SSH1ΔN-Flag with GFP-p62 in HT22 cells. SSH1ΔN
significantly reduced both the number of GFP-p62 puncta and GFP-p62 puncta recruited
to Tom20+ mitochondria at steady state and after treatment with FCCP (Fig. 12 E-G),
essentially identical to that seen with full-length SSH1. In contrast, the catalytically dead
SSH1ΔN-C393S mutant failed to alter GFP-p62 puncta or their association with
mitochondria (Supplemental Fig. S4 C-E), indicating that the catalytic phosphatase
activity is required for these effects. Moreover, SSH1ΔC had no significant effect on either
GFP-p62 puncta number or its recruitment to mitochondria (Fig. 12 H-J), indicating that
the sole ability of SSH1 to dephosphorylate cofilin is insufficient for inhibition of p62. As
expected, SSH1ΔN significantly reduced endogenous p62-ubiquitin complexes in PLA
experiments (Fig. 12 K, L). Hence, these data collectively demonstrate the modular
activity of SSH1 on p62 via dephosphorylation, which requires catalytic activity on p62
and is separable from that on cofilin.
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Figure 12 A-D. Direct dephosphorylation of pSer403-p62 by SSH1 is separable from
cofilin dephosphorylation
A. Schematic of full length SSH1 and SSH1 mutants.
B. Representative blots of total p62, pSer403-p62 and pSer3-cofilin from HT22 cells transfected
with vector control (p3xFlag), Flag-SSH1ΔN, Flag-SSH1ΔN-CS, or CFP-SSH1ΔC.
C. Quantitative graph of figure B expressed as means ± SEM, one-way ANOVA with Tukey’s
posthoc test, n=4/condition, #p<0.0001 (control vs. SSH1ΔN).
D. Representative blots from recombinant p62 purified from Sf9 inset cells incubated with
recombinant SSH1 variants for the indicated times and immunoblotted for pS403-p62, showing
dephosphorylation of p62 by SSH1ΔN but not SSH1ΔC.
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Figure 12 E-G. Direct dephosphorylation of pSer403-p62 by SSH1 is separable from
cofilin dephosphorylation
E. Representative images at 4h FCCP condition with white insets magnified. HT22 cells cotransfected with GFP-p62 and vector control (p3xFlag) or Flag-SSH1ΔN, treated with 5µM FCCP
for 4h, 2h, 0.5h, or 0h (DMSO), and subjected to staining for Flag-M2 (dark blue) and Tom20 (red)
or direct imaging for GFP-p62 (green).
F-G. Quantitative graphs of figure E expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n>15/condition from 3 different experiments, *p<0.05, ***p<0.0005.
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Figure 12 H-J. Direct dephosphorylation of pSer403-p62 by SSH1 is separable from
cofilin dephosphorylation
H. Representative images at 4h FCCP condition with white insets magnified. HT22 cells cotransfected with GFP-p62 and vector control (p3xFlag), Flag-SSH1, or Flag-SSH1ΔC, treated with
5µM FCCP for 4h, 2h, 0.5h, or 0h (DMSO), and subjected to staining for Flag-M2 (light blue) and
Tom20 (red) or direct imaging for GFP-p62 (green).
I-J. Quantitative graphs of figure H expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n>20/condition from 3 different experiments, *p<0.05, **p<0.005, #p<0.0001.
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Figure 12 K-L. Direct dephosphorylation of pSer403-p62 by SSH1 is separable
from cofilin dephosphorylation
K. Representative images from HT22 cells transfected with vector control (p3xFlag) or FlagSSH1ΔN, subjected to in situ PLA for p62-ubiquitin complexes (red), and staining for Flag-M2
(green) and DAPI (light blue).
L. Quantitative graph of figure K expressed as means ± SEM, t-test, n>20/condition from 3
different experiments, #p<0.0001.
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CHAPTER 5

SSH1 EXACERBATES AND SSH1 REDUCTION RESCUES P62 FLUX AND
AUTOPHAGIC CLEARANCE IN TAU-P301S NEURONS AND BRAINS

Endogenous SSH1 and SSH1ΔN impair p62 flux and ubiquitin binding in primary
neurons
To confirm the effects of SSH1 on p62 in primary neurons, we generated and purified
high titer (>1012 vg/mL) control and SSH1ΔN rAAV9, control and SSH1-shRNA rAAV9,
as well as mCherry-GFP-p62 rAAV9. On DIV4, we transduced wild type neurons with
mCherry-GFP-p62 rAAV9 and control or SSH1ΔN rAAV9. In a different set of experiments,
we also transduced neurons with mCherry-GFP-p62 rAAV9 with control or SSH1-shRNA
rAAV9. On DIV20, we quantified p62 puncta, acidified red-only p62 puncta, and
percentage of acidified red-only p62 with or without FCCP treatment for 4h. Expression
of SSH1ΔN significantly decreased total p62 puncta (Fig. 13 A, B), red-only puncta (Fig.
13 A, C), and percentage of red-only puncta (Fig. 13 A, D) in both the absence and
presence of FCCP. Conversely, SSH1 shRNA significantly increased total p62 puncta
(Fig. 13 E, F), acidified red-only p62 puncta (Fig. 13 E, G), and percentage of red-only
p62 puncta (Fig. 13 E, H) together with loss of SSH1 expression (Fig. 13 E) in both the
absence and presence of FCCP, indicating that SSH1 reduction promotes p62 flux to
lysosomes in neurons. Assessment of endogenous p62-ubiquitin complexes by in situ
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PLA confirmed that SSH1ΔN significantly reduces the p62-ubiquitin complex (Fig. 13 I,
J), whereas SSH1-shRNA significantly enhances the p62-ubiquitin complex (Fig. 13 K,
L). Western blotting from primary neuronal lysates confirmed the expression of SSH1ΔN
with the expected reduction in pSer403-p62 (Supplemental Fig. S5 A), as well as efficient
knockdown of endogenous SSH1 by SSH1-shRNA with the expected increase in
pSer403-p62 (Supplemental Fig. S5 B).

SSH1ΔN exacerbates and SSH1 reduction partially rescues p62 flux in tauP301S
brains
Previous studies have shown that p62 targets misfolded tau for autophagic clearance.
Specifically, p62/SQSTM1 knockout mice display severe neurodegeneration as well as
hyperphosphorylated tau and neurofibrillary tangles (Ramesh Babu et al., 2008), and p62
overexpression strongly reduces pathogenic tau in transfected cells and in vivo (Xu et al.,
2019). Conversely, accumulation of pathogenic tau adversely deregulates autophagy, as
evidenced by abnormal accumulation of autophagosomes and LC3 (Feng et al., 2019;
Hebron et al., 2014; Lin et al., 2003; Nixon et al., 2005), suggestive of a maladaptive feedforward cycle of tauopathy and autophagy deregulation. However, p62 flux in the setting
of tauopathy in vivo has not been investigated. Thus, we used the tauP301S mice (PS19),
in which tauopathy starts at 3 months and progressively becomes more filamentous at 6
months of age (Yoshiyama et al., 2007). To assess whether p62 flux is altered in
tauP301S brains and whether the non-cofilin component of SSH1 (SSH1ΔN) alters p62
flux in vivo, we injected high titer (>1012 vg/mL) mCherry-GFP-p62 rAAV9 with control or
SSH1ΔN-flag rAAV9 into the hippocampus of 3-month old tauP301S mice. We also
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injected control wild type littermate hippocampus with mCherry-GFP-p62 rAAV9 and
vector control rAAV9. Two months post-injection, we processed brains for histological
detection and quantification of mCherry, GFP, SSH1, and phospho-tau (pS199/pS202) in
the CA3 region of the hippocampus where mCherry-GFP-p62 was homogenously
expressed. Total p62 puncta number per cell was significantly higher in tauP301S CA3
compared to wild type CA3 by ~40% (Fig. 14 A, B1). The percentage of acidified red-only
p62 puncta was close to 80% in wild type CA3 (Fig. 14 A, B2), indicating healthy p62 flux;
however, the percentage of acidified red-only p62 puncta was significantly reduced to
~50% in CA3 of tauP301S brains (Fig. 14 A, B2), indicative of p62 flux impairment in
tauP301S brains. Similar p62 flux impediment was observed in DIV20 tauP301S primary
neurons compared to littermate WT neurons (Fig. 15 A, B), indicating an early phenotype
intrinsic to tauP301S expression. Expression of SSH1ΔN in tauP301S brains significantly
reduced total p62 puncta number per cell (Fig. 14 A, B1) as well as percentage of acidified
red-only p62 puncta such that less than 30% of p62 puncta were red-only (Fig. 14 A, B2),
indicating that SSH1ΔN worsens p62 flux in tauP301S brains. This exacerbated
impediment of p62 flux by SSH1ΔN was accompanied by a significant 30% increase in
pS199/pS202-tau immunoreactivity in CA3 (Fig. 14 D), indicating that SSH1ΔN impairs
p62-mediated phospho-tau clearance. Indeed, Western blotting from dissected
hippocampus confirmed the expression of SSH1ΔN-Flag (M2) together with markedly
increased total tau but equivalent levels of mCherry-GFP-p62 (GFP antibody) and actin
(Fig. 14 E). As seen in tauP301S brains, overexpression of full-length SSH1 or SSH1ΔN
but not SSH1ΔC significantly increased tau levels in Hela-V5-tau cells (Woo et al., 2017b)
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stably expressing human wild type tau (4R0N) (Fig. 15 E-H), confirming that the p62 but
not cofilin component of SSH1 increases tau levels.
We next assessed whether knockdown of endogenous SSH1 can rescue the p62
flux impediment in tauP301S brains. Hence, we injected high titer (>1012 vg/mL) mCherryGFP-p62 rAAV9 together with control or SSH1-shRNA rAAV9 into the hippocampus of
tauP301S mice at 3 months of age and processed brains for assessment at 5 months of
age. The percentage of red-only p62 puncta were again close to 50% in control rAAV9
injected tauP301S hippocampal CA3 (Fig. 14 F, G2). However, SSH1-shRNA rAAV9
significantly increased the percentage of red-only puncta to ~70% and markedly reduced
endogenous SSH1 staining in CA3 (Fig. 14 F, G1, G2), indicating that SSH1 reduction
partially rescues the p62 flux impairment in tauP301S brains. This enhancement of p62
flux by SSH1 shRNA was accompanied by a significant 30% decrease in pS199/pS202tau immunoreactivity in CA3 (Fig. 14 H, I), indicating that SSH1 reduction enhances p62mediated phospho-tau clearance. Western blotting from dissected hippocampus
confirmed that SSH1-shRNA lowers endogenous SSH1 by ~70% together with marked
reduction in total tau but equivalent levels of mCherry-GFP-p62 (GFP antibody) and actin
(Fig. 14 J). Therefore, these results taken together demonstrate that while tauP301S
expression impedes p62 flux in vivo, SSH1ΔN expression significantly exacerbates p62
flux and increases phospho-tau levels, whereas knockdown of endogenous SSH1
reduction partially rescues p62 flux and significantly lowers phospho-tau levels in
tauP301S brains.
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Figure 13 A-D. Endogenous SSH1 and SSH1ΔN impair p62 flux and p62-ubiquitin
binding in primary neurons
A. Representative images at 4h FCCP condition with white insets magnified. WT primary
hippocampal neurons co-transduced with AAV9-mCherry-GFP-p62 and AAV9-Control or FlagSSH1ΔN, treated with 2µM FCCP for 4h or 0h (DMSO) and subjected to staining for Flag-M2
(dark blue) and DAPI (light blue) or direct imaging (mCherry: red, GFP: green).
B-D. Quantitative graphs of figure A expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n>15/condition from 3 different experiments, *p<0.05, **p<0.005, ***p<0.0005
(control vs. SSH1ΔN).

58

Figure 13 E-H. Endogenous SSH1 and SSH1ΔN impair p62 flux and p62-ubiquitin
binding in primary neurons
E. Representative images at 4h FCCP condition with white insets magnified. WT primary
hippocampal neurons co-transduced with AAV9-mCherry-GFP-p62 and AAV9-control shRNA or
SSH1-shRNA, treated with 2µM FCCP for 4h or 0h (DMSO) and subjected to staining for SSH1
(dark blue) and DAPI (light blue) or direct imaging (mCherry: red, GFP: green).
F-H. Quantitative graph of figure E expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n>15/condition from 3 different experiments, *p<0.05, **p<0.005, **p<0.005,
#p<0.0001 (control-shRNA vs. SSH1-shRNA).
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Figure 13 I-L. Endogenous SSH1 and SSH1ΔN impair p62 flux and p62-ubiquitin
binding in primary neurons
I. Representative images with white insets magnified. WT primary hippocampal neurons
transduced with AAV9-Flag-control or Flag-SSH1ΔN and subjected to in situ PLA for p62-ubiqutin
complexes (red) and staining for M2-Flag (green) and DAPI (light blue).
J. Quantitative graph of figure I expressed as means ± SEM, t-test, n>15/condition from 3 different
experiments, #p<0.0001.
K. Representative images from WT primary hippocampal neurons transduced with AAV9-GFP or
SSH1-shRNA-GFP and subjected to in situ PLA for p62-ubiqutin complexes (red) and staining for
DAPI (light blue) or direct imaging for GFP (green).
L. Quantitative graph of figure K expressed as means ± SEM, t-test, n=10/condition from 3
different experiments, #p<0.0001
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Figure 14 A-B. SSH1ΔN exacerbates and SSH1 reduction partially rescues p62 flux
in tauP301S brains
3-month old WT and tauP301S mice co-injected with AAV9-mCherry-GFP-p62 and AAV9-Flagcontrol or Flag-SSH1ΔN and sacrificed 2-months post-injection at 5 months of age.
A. Representative images showing staining for Flag-M2 (dark blue) and DAPI (light blue) or direct
fluorescence for mCherry-GFP-p62 (mCherry: red, GFP: green) in the hippocampus CA3 region.
B. Quantitative graphs of figure A expressed as means ± SEM, 1-way ANOVA, Tukey’s posthoc
test, n=6 mice/condition *p<0.05, **p<0.005.
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Figure 14 C-E. SSH1ΔN exacerbates and SSH1 reduction partially rescues p62 flux
in tauP301S brains
3-month old tauP301S mice co-injected with AAV9-mCherry-GFP-p62 and AAV9-Flag-control or
Flag-SSH1ΔN and sacrificed 2-months post-injection at 5 months of age.
C. Representative images showing staining for pS199/pS202-tau (dark blue) and DAPI (light blue)
and direct imaging for mCherry-GFP-p62 (mCherry: red, GFP: green) in the hippocampus CA3
region of tauP301S mice.
D. Quantitative graph of figure C (pS199/pS202-tau) expressed as means ± SEM, t-test, n=6
mice/condition *p<0.05.

E. Representative blots of total tau from dissected hippocampus of injected tauP301S
mice.
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Figure 14 F-G. SSH1ΔN exacerbates and SSH1 reduction partially rescues p62 flux
in tauP301S brains
3-month old tauP301S mice co-injected with AAV9-mCherry-GFP-p62 and AAV9-control-shRNA
or AAV9-SSH1-shRNA and sacrificed 2-months post-injection at 5 months of age.
F. Representative images showing staining for SSH1 (dark blue) and DAPI (light blue) or direct
fluorescence for mCherry-GFP-p62 (mCherry: red, GFP: green) in the hippocampus CA3 region.
G. Quantitative graphs of figure F expressed as means ±SEM, t-test, n=6 mice/condition *p<0.05,
**p<0.005.
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Figure 14 H-J. SSH1ΔN exacerbates and SSH1 reduction partially rescues p62 flux
in tauP301S brains
3-month old tauP301S mice co-injected with AAV9-mCherry-GFP-p62 and AAV9-control-shRNA
or AAV9-SSH1-shRNA and sacrificed 2-months post-injection at 5 months of age.
H. Representative images showing staining for pS199/pS202-tau (dark blue) and DAPI (light blue)
and direct imaging for mCherry-GFP-p62 (mCherry: red, GFP: green) in the hippocampus CA3
region of tauP301S mice.
I. Quantitative graph of figure H (pS199/pS202-tau) expressed as means ± SEM, t-test, n=6
mice/condition *p<0.05.
J. Representative blots of total tau and SSH1 from dissected hippocampus of injected tauP301S
mice.
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Figure 15 A-D. SSH1ΔN exacerbates and SSH1 reduction partially rescues p62 flux
in tauP301 brains
A. Representative images of 4h FCCP condition with white insets magnified. WT and tauP301S
neurons co-transduced with AAV9-mCherry-GFP-p62 and AAV9-Flag-control or Flag-SSH1ΔN,
and subjected to staining for Flag-M2 (dark blue) and DAPI (light blue) or direct imaging for
mCherry-GFP-p62 (red & green).
B. Quantitative graphs of figure A expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=15/condition from 3 different experiments, *p<0.05, **p<0.005.
C. Representative images of 4h FCCP condition with white insets magnified. TauP301S neurons
co-transduced with AAV9-mCherry-GFP-p62 and AAV9-control shRNA or AAV9-SSH1-shRNA,
and subjected to staining for SSH1 (dark blue) and DAPI (light blue) or direct imaging for mCherryGFP-p62 (red & green).
D. Quantitative graphs of figure C expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=15/condition from 3 different experiments, *p<0.05.
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Figure 15 E-H. SSH1ΔN exacerbates and SSH1 reduction partially rescues p62 flux
in tauP301 brains
E. Representative blots of total tau from Hela-V5-Tau cells transfected with vector control
(p3xFlag), Flag-SSH1, or Flag-SSH1ΔN.
F. Quantitative graph of figure E expressed as means ± SEM, 1-way ANOVA, Tukey’s posthoc
test, **p<0.005.
G. Representative blots of total tau from Hela-V5-Tau cells transfected with control (GFP), GFPSSH1, or GFP-SSH1ΔC.
H. Quantitative graph of figure G expressed as means ± SEM, 1-way ANOVA, Tukey’s posthoc
test, **p<0.005.

66

CHAPTER 6

DISCUSSION

Accumulation of misfolded proteins and damaged mitochondria constitute pathological
signatures of neurodegenerative diseases. These features, in large part, are attributed to
impairments in selective autophagy and mitophagy, vital cellular processes that remove
polyubiquitinated substrates tagged for clearance (reviewed in Levine and Kroemer, 2009,
Chen and Chan, 2009) (reviewed by Kerr, 2017). P62/SQSTM1 is a major selective
autophagy cargo receptor that plays a key role in targeting misfolded tau and damaged
mitochondria for degradation. This is achieved by the activating phosphorylation of p62
on Ser403 by ULK, TBK1, or CK2, which increases p62 affinity for polyubiquitinated
substrates (Katsuragi et al., 2015; Matsumoto et al., 2015; Sanchez-Martin and Komatsu,
2018) and activates the recruitment of LC3 (Jiang and Mizushima, 2015; Katsuragi et al.,
2015). This phosphorylation is transient and subject to rapid dephosphorylation
(Matsumoto et al., 2015). However, to date, the identity of phosphatases that
physiologically mediate p62 dephosphorylation on pSer403 has remained mysterious. In
this study, we identified SSH1 as the first phosphatase that deactivates p62 by
dephosphorylation of pSer403. This event resulted in fewer but larger p62 puncta and
reduced binding to ubiquitinated substrates, thereby significantly slowing p62 flux. As
cargo-bound p62 acts as an autophagy inducer by enhancing the synthesis of LC3 and
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its conversion to LC3-II (Cha-Molstad et al., 2017), SSH1-mediated dephosphorylation of
p62 also resulted in impaired downstream LC3 puncta formation, reduced LC3-II
generation, and slowed mitophagy without directly altering LC3 flux to lysosomes. The
inhibitory actions of SSH1 on p62 were dependent on the UBA domain Ser403 p62
phosphorylation site, and SSH1ΔN but not SSH1ΔC was sufficient to directly
dephosphorylate pSer403-p62 and inhibit p62 activity, thereby separating the canonical
function of SSH1 on cofilin from p62. This inhibitory action of SSH1 on p62 was validated
in primary neurons and in vivo. Specifically, p62 flux was impaired in tauP301S primary
neurons and brains, which was exacerbated by expression of SSH1ΔN in brain resulting
in increased phospho-tau accumulation. Conversely, shRNA-mediated knockdown of
endogenous SSH1 partially rescued p62 flux in tauP301S brains resulting in reduced
phospho-tau levels. These results taken together identify a novel bipartite function of
SSH1 as an upstream inhibitor of p62, separate from its action on cofilin, and implicate
the SSH1-p62 pathway in impaired clearance of misfolded tau.

Inhibition of p62 by SSH1-mediated dephosphorylation of pSer403
The ability of p62 to function as selective autophagy cargo receptor depends on three
essential domains. N-terminal PB1 domain mediates the self-interaction of p62 allowing
the formation of p62 helical filaments arranged in a head to tail configuration (Ciuffa et al.,
2015). These filaments function as scaffolds for the binding to multiple LC3 through LIR
domain, thereby allowing the nucleation of the autophagosome membrane together with
p62 (Katsuragi et al., 2015). The UBA domain of p62 mediates the binding to ubiquitinated
cargo (Matsumoto et al., 2011), and such binding is regulated by several processes. First,
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homodimerization of the UBA domain precludes polyubiquitin binding and contributes to
p62 puncta abundance (Isogai et al., 2011; Long et al., 2010), as deletion of the UBA
domain impairs both ubiquitin binding and formation of p62 bodies even in the presence
of the PB1 domain (Ciuffa et al., 2015; Matsumoto et al., 2011). Second, Ser403
phosphorylation within the UBA domain destabilizes UBA homodimerization and liberates
the UBA domain from dimeric repression (Katsuragi et al., 2015), thereby facilitating the
binding to polyubiquitinated cargo. A third regulatory process via direct ubiquitination of
the UBA domain on K420 has also recently been shown to modulate binding to
ubiquitinated cargo (Lee et al., 2017; Peng et al., 2017). Our observation that SSH1
dephosphorylates pSer403 of p62, reduces p62 puncta number while increasing puncta
size, and decreases ubiquitin binding is consistent with the expected increase in UBA
domain homodimerization by pSer403 dephosphorylation. Our co-IP and PLA
experiments to detect p62 self-interaction at the molecular level, however, did not find a
measurable change in overall p62 self-interaction. This is likely due to the sufficiency of
the PB1 domain to maintain p62 self-interaction at the molecular level, whereas puncta
size is governed by PB1 oligomerization and UBA dimerization, the latter which inhibited
by Ser403 phosphorylation (Katsuragi et al., 2015). In addition, a recent study showed
that polyubiquitin binding to the UBA domain promotes fragmentation of p62 filaments
(Ciuffa et al., 2015). Hence, SSH1-induced inhibition of p62-ubiqutin binding may also
account for the observed reduction in p62 puncta number but increased puncta size.
Consistent with either or both scenarios, we validated our findings using the p62-S403E
phosphomimetic mutant, which produced an identical phenotype to that seen with SSH1
knockdown resulting in increased p62 puncta number and reduced the puncta size.
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Conversely, p62-S403A ‘inactive’ mutant produced an identical phenotype to that seen
with SSH1 overexpression, resulting in reduced p62 puncta number and increased puncta
size. Neither SSH1 knockdown nor overexpression could alter these molecular signatures
of S403E or S403A mutants, demonstrating the requirement of Ser403 modification in
SSH1-induced inhibition of p62. These results therefore indicate that SSH1-mediated
dephosphorylation of pSer403-p62, like the S403A mutant, decreases the number of
active p62 puncta by coalescing smaller puncta into larger particles containing dimerized
UBA domain. We found no evidence that SSH1 alters the activating phosphorylation
(pSer317) of ULK (not shown), a key upstream kinase that phosphorylates Ser403-p62
and a kinase shown to be essential for LC3 lipidation (Pengo et al., 2017). Moreover, our
observation that SSH1ΔN, but not SSH1ΔC, dephosphorylates pSer403-p62 using
purified recombinant proteins provides cogent evidence for a direct effect of SSH1 in p62
inhibition.

Regulation of LC3 biogenesis and recruitment by SSH1
The interaction of p62 with LC3 is essential for p62-mediated selective autophagy. Under
conditions of proteotoxic stress or mitochondrial damage, autophagy or mitophagy is
initiated and regulated by the cargo. Recent studies indicate that cargo-bound p62
stimulates LC3-positive puncta formation colocalized with p62, increases the synthesis of
LC3 and its conversion to a lipidated form, LC3-II (Cha-Molstad et al., 2017; Pankiv et al.,
2007). Our observation that SSH1-mediated p62 dephosphorylation reduces LC3-II
generation, LC3 puncta, and LC3 recruitment to mitochondria upon depolarization is
consistent with this notion. Indeed, we validated that these effects on LC3 are completely
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dependent on the presence of p62, as p62 knockdown abrogated the effects of SSH1 on
LC3 puncta and recruitment. The reduction in LC3-II level by SSH1 was not due to faster
removal by the lysosome, as bafilomycin-induced accumulation of LC3-II was not altered
by SSH1 upon induction of autophagy or mitophagy by rapamycin or FCCP, respectively.
Hence, despite the changes in LC3 puncta formation, SSH1 did not alter its flux as seen
by the mCherry-GFP-LC3 flux reporter. In contrast, SSH1 significantly slowed FCCPinduced mitophagy flux as seen by the mito-keima flux reporter, which is reflected in
reduced LC3 puncta formation and its overall recruitment to mitochondria. As SSH1 did
not alter LC3 flux, we looked for upstream effectors that may account for changes in LC3.
It is notable that optineurin, a p62-related autophagy cargo receptor of similar function,
was not affected by SSH1. This confirms the specificity of SSH1 on p62, which was
validated by p62 deletion and phosphorylation mutants.

Divergent activities of SSH1 on p62 and cofilin: Implications for tauopathy
SSH1 is a phosphatase classically known for its ability to dephosphorylate and activate
cofilin (Niwa et al., 2002), a major F-actin severing protein implicated in a wide array of
biological processes (Bernstein and Bamburg, 2010). We found that SSH1
dephosphorylates pSer403 of p62, which was modular and separable from that on pSer3
of cofilin. This discovery not only identified SSH1 as the first phosphatase with this activity,
but also indicated that 2 major and apparently unrelated pathways (cofilin & p62) are
regulated by a single phosphatase. The cofilin binding site is located within the N-terminal
region (Kurita et al., 2008), while the p62 binding site is in the C-terminal region, with the
shared catalytic domain located in between. At present, it is unknown whether both
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activities of SSH1 are regulated simultaneous or separately. However, previous studies
have shown that SSH1 is activated by oxidative stress. Specifically, the binding and
sequestration of SSH1 by 14-3-3 inhibits SSH1 activity; however, upon oxidation of 14-33, SSH1 is released from 14-3-3 inhibitory control, thereby allowing SSH1 to
dephosphorylate and activate cofilin (Eiseler et al., 2009; Kim et al., 2009b). We and
others have previously shown that Aβ42 oligomers activate cofilin (Maloney and Bamburg,
2007; Woo et al., 2012; Woo, 2015), a process that requires reactive oxygen species
(ROS) generation by NOX (Walsh et al., 2014) and dephosphorylation of cofilin by SSH1
(Woo, 2015). Aβ42 oligomer-induced activation of cofilin has been shown to destabilize
F-actin at the synapse and translocate to mitochondria to promote mitochondrial
dysfunction (Woo, 2015). As SSH1 reduction mitigates Aβ42 oligomer-induced
mitochondrial translocations of cofilin, our observation that SSH1 knockdown robustly
promotes an early step in mitophagy, LC3 recruitment to mitochondria, is rather surprising
and suggests that oxidative stress may simultaneously induce mitochondrial damage and
impair mitochondrial clearance through SSH1 activation, a hypothesis that requires
validation.
The implications of the dual and divergent functions of SSH1 in tau biology and
tauopathy are multi-fold. We recently reported that cofilin reduction mitigates tauopathy
through reduced displacement of tau from microtubules, as activated / dephosphorylated
cofilin promotes tau displacement from microtubules; however, activated cofilin does not
directly regulate tau levels (Woo et al., 2019). This was also evidenced in this study, in
which SSH1ΔC, which selectively dephosphorylates cofilin, failed to increase tau,
whereas SSH1ΔN, which selectively dephosphorylates p62, significantly increased tau
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as effectively as full-length SSH1. Indeed, we confirmed that SSH1ΔN enhances tau and
phospho-tau levels in brain. By using the mCherry-GFP-p62 flux reporter, we found that
tauP301S brains and primary neurons exhibit significantly impaired p62 flux, in line with
observations that pSer403-p62 per total p62 is dramatically reduced in brains of AD
patients (Tanji et al., 2014). This impairment was exacerbated by SSH1ΔN, resulting in a
corresponding increase in phospho-tau, while tauP301S-induced impairment in p62 flux
was partially rescued by SSH1-shRNA, resulting in a corresponding decrease in
phospho-tau. Hence, in addition to the SSH1-cofilin activation pathway in promoting tau
displacement from microtubules (Woo et al., 2019), this study highlights the divergent
SSH1-p62 inhibitory pathway in impairing autophagic clearance of misfolded tau.
Therefore, partially inhibiting SSH1 activity may be an effective mitigating strategy to
reduce tauopathy.

73

CHAPTER 7

METHODS

Experimental model and subject details
Cell lines: Mouse hippocampus derived HT22 neuroblastoma cells (Professor David
Schubert;
Salk Institute(Li et al., 1997b)), human embryonic kidney cell line HEK293 cells (ATCC,
Cat # CRL-1573), human embryonic kidney cell line HEK293T cells (ATCC, Cat # CRL3216) and stably transfected Hela-V5-tau cells (Dr. Chad Dickey(Woo et al., 2017b))
overexpressing wild-type 4R0N human tau were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Thermo Scientific, MA, USA) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin (P/S).

Mice: WT and tauP301S (Yoshiyama et al., 2007) mice were obtained from the Jackson
Laboratory and bred in the C57BL/6 background. Mice were housed together until the
time they were introduced with AAV9 at 3 months of age. Water and food were supplied
ad libitum with 12-hour light/dark cycle under standard vivarium conditions. All mice were
sacrificed at 5 months of age.
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Primary neurons: Hippocampal and cortical primary neuron from WT and tauP301S mice
were prepared from P0 pups as previously described (Woo et al., 2017a; Woo et al.,
2015b). In brief, both hippocampus and cortex were dissected separately in ice-cold
HBSS and digested with trypsin. Mouse neurons were plated on glass coverslips or plates
coated with poly-d-lysine (Sigma-Aldrich, St. Louis, MO, USA) in neurobasal medium
(Invitrogen, Carlsbad, CA, USA), 2% Glutamax, and 2% B27 supplement (Invitrogen,
Carlsbad, CA, USA). All the cells were cultured in a humidified atmosphere (5% CO2) at
37℃.

Key resources
Antibodies: Rabbit polyclonal Anti-LC3A/B (Cell Signaling Technology, Cat # 4108);
Rabbit Polyclonal Anti-Slingshot-1L (C-terminal region) (ECM Biosciences, Cat #
SP1711); Rabbit monoclonal Anti-SSH1 (E1K3W) (Cell Signaling Technology, Cat #
13578); Rabbit monoclonal Anti-Tom20 (D8T4N) (Cell Signaling Technology, Cat #
42406); Mouse monoclonal Anti-FLAG® M2 (Sigma-Aldrich, Cat # F3165); Mouse
monoclonal Anti-β-Actin (Sigma-Aldrich, Cat # A5316); Rabbit polyclonal AntiSQSTM1/p62 (Cell Signaling Technology, Cat # 5114); Rabbit polyclonal Anti-PhosphoSQSTM1/p62 (Ser403) (Cell Signaling Technology, Cat # 14354); Rabbit monoclonal
Anti-Phospho-SQSTM1/p62 (Ser403) (D8D6T) (Cell Signaling Technology, Cat #
39786); Mouse monoclonal Anti-HA-Tag (6E2) (Cell Signaling Technology, Cat # 2367);
Rabbit monoclonal Anti-GFP (D.5.1) XP® (Cell Signaling Technology, Cat # 2956);
Mouse monoclonal Anti-Ubiquitin (P4D1) (Santa Cruz Biotechnology, Cat # sc-8017);
Rabbit monoclonal Anti-Cofilin (D3F9) XP® (Cell Signaling Technology, Cat # 5175);
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Rabbit monoclonal Anti-Phospho-Cofilin (Ser3) (77G2) (Cell Signaling Technology, Cat
# 3313); Rabbit monoclonal Anti-His-Tag (D3I1O) XP® (Cell Signaling Technology, Cat
# 12698); Mouse monoclonal Anti-Tau (A10) (Santa Cruz Biotechnology, Cat # sc390476); Rabbit polyclonal Anti-phospho-Tau (pSer199/202) (Sigma-Aldrich, Cat #
T6819); Polyclonal Mouse Anti-Horseradish Peroxidase (Jackson ImmunoResearch
Inc., Code: 223-005-024, RRID: AB_2339261); Polyclonal Rabbit Anti-Horseradish
Peroxidase (Jackson ImmunoResearch Inc., Code: 323-005-024, RRID: AB_2315781);
Polyclonal Goat Anti-Horseradish Peroxidase (Jackson ImmunoResearch Inc., Code:
123-005-021, RRID: AB_2338952); Donkey anti-Rabbit IgG (H+L) Highly CrossAdsorbed Secondary Antibody, Alexa Fluor Plus 594 (Invitrogen, Cat # A32754);
Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor
Plus 594 (Invitrogen, Cat # A32744); Goat anti-Rabbit IgG (H+L) Cross-Adsorbed
Secondary Antibody, Alexa Fluor 405 (Invitrogen, Cat # A-31556); Goat anti-Mouse IgG
(H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 405 (Invitrogen, Cat # A31553); Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody,
Alexa Fluor Plus 647 (Invitrogen, Cat # A32795); Donkey anti-Mouse IgG (H+L) Highly
Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 647 (Invitrogen, Cat # A32787);
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor
Plus 488 (Invitrogen, Cat # A32790); Donkey anti-Mouse IgG (H+L) Highly CrossAdsorbed Secondary Antibody, Alexa Fluor Plus 488 (Invitrogen, Cat # A32766)
Reagents, Chemicals, Peptides, Recombinant Proteins, and Oligonucleotides: Agarose
Linked Antisera Anti-Mouse IgG Kit (American Qualex, Cat # G1060); Agarose Linked
Antisera Anti-Rabbit IgG Kit (American Qualex, Cat # G1360B); MitoTracker® Red
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CMXRos (Cell Signaling Technology, Cat # 9082); DAPI (Sigma-Aldrich, Cat #D9542);
Duolink® In Situ PLA® Probe Anti-Mouse PLUS (Sigma-Aldrich, Cat # DUO92001);
Duolink® In Situ PLA® Probe Anti-Rabbit MINUS (Sigma-Aldrich, Cat # DUO92005);
Duolink® In Situ Detection Reagents Red (Sigma-Aldrich, Cat # DUO92008); Duolink®
In Situ Wash Buffers, Fluorescence (Sigma-Aldrich, Cat # DUO82049); Duolink® In Situ
Mounting Medium with DAPI (Sigma-Aldrich, Cat # DUO82040); Pierce BCA Protein
Assay Kit (Thermo Scientific, Cat # 23225); Aligent QuikChange II Site-Directed
Mutagenesis Kit (Agilent, Cat # 200521); FCCP (Sigma-Aldrich, Cat # C2920);
Rapamycin (Sigma-Aldrich, Cat # R8781); Bafilomycin (Santa Cruz Biotechnology, Cat
# sc-201550); Benzonase® Nuclease (Sigma-Aldrich, Cat # E1014); OptiPrep™ Density
Gradient Medium (Sigma-Aldrich, Cat # D1556); Lipofectamine 2000 (Invitrogen, Cat #
11668019); Fluorochrome mounting solution (Thermo scientific, Cat # TA-030-FM);
Opti-MEM I (1x) (Gibco, Cat # 31985-070); Paraformaldehyde, 96% Extra pure. (PFA)
(Acros Organics, Cat # 416780030); DMEM (Dulbecco's Modified Eagle Medium)
(Corning, Cat # 10-013-CV); Fetal Bovine Serum (FBS) (Sigma- Aldrich, Cat # 12306C);
Pen Strep (P/S) (Gibco, Cat # 15140-122); BM-Cyclin (Roche, Cat # 10799050001); Sf900™ II SFM (Gibco, Cat # 10902096); GE Healthcare Ni Sepharose (GE Healthcare,
Cat# 17526801); XhoI restriction enzyme (NEW ENGLAND Biolabs, Cat #R0146S);
AgeI restriction enzyme (NEW ENGLAND Biolabs, Cat #R0552S); AscI restriction
enzyme (NEW ENGLAND Biolabs, Cat #R0558S); NheI restriction enzyme (NEW
ENGLAND Biolabs, Cat #R0131S); NotI restriction enzyme (NEW ENGLAND Biolabs,
Cat #R0189S); SalI restriction enzyme (NEW ENGLAND Biolabs, Cat #R0138S); SpeI
restriction enzyme (NEW ENGLAND Biolabs, Cat #R0133S); Beta-Amyloid 1-42, TFA
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(GenicBio Limited, Cat # A-42-T-1); SSH1 siRNA: GAG GAG CUG UCC CGA UGA C
(Dharmacon GE Healthcare, Cat # CTM-395590); SignalSilence® SQSTM1/p62 siRNA
II (Cell Signaling Technology, Cat # 6399); SSH1ΔC-his, SSH1ΔN-his, SQSTM1/p62his were generated by this paper (see method details).
Recombinant DNA: pN3-3xFlag-Control (Addgene: Guntram Suske Lab, Cat #
107717(Stielow et al., 2018)); pmRFP-LC3 (Addgene: Tamotsu Yoshimori Lab, Cat #
21075(Kimura et al., 2007)); pMXs-puro GFP-p62 (Addgene: Noboru Mizushima Lab,
Cat # 38277(Itakura and Mizushima, 2011)); pBABE-puro mCherry-EGFP-LC3B
(Addgene: Jayanta Debnath Lab, Cat # 22418(N'Diaye et al., 2009)); pBABE-EGFP
(Addgene: Debu Chakravarti Lab, Cat # 36999(Parker et al., 2012)); ECFP-SSH1ΔC
(N461) (Dr. Mizuno lab(Kurita et al., 2008)); EGFP-SSH1 (Dr. Storz lab(Eiseler et al.,
2009)); mKeima-Red-Mito-7 (Addgene, Cat # 56018 ); pOPTN-EGFP (Addgene:
Beatrice Yue Lab, Cat # 27052(Park et al., 2006)); pMXs-puro GFP-p62ΔC (Addgene:
Noboru Mizushima Lab, Cat # 38282(Itakura and Mizushima, 2011)); pMXs-puro GFPp62 D337, 338, 339A (GFP-p62-LIR) (Addgene: Noboru Mizushima Lab, Cat #
38280(Itakura and Mizushima, 2011)); HA-Ubiquitin (Addgene: Edward Yeh Lab, Cat #
18712(Kamitani et al., 1997)); pDR125 (Addgene: Dale Ramsden Lab, Cat # 37150);
pN3-3xFlag-SSH1, mCherry-EGFP-p62, mCherry-EGFP-p62-S403A, mCherry-EGFPp62-S403E, pN3-Flag-SSH1ΔC, pN3-Flag-SSH1ΔN and pN3-Flag-SSH1ΔN-C393S
were generated by this paper (see method details).
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Method details
Ethics approval: All experimental methods and protocols involving mice were approved
by Institutional Animal Care and Use Committee (IACUC) at the University of South
Florida (USF). IACUC and Institutional Biosafety Committees (IBC) at the USF have also
approved that all the methods used in this study were performed in accordance with the
relevant guidelines and regulations.

DNA transfections and adenoviral transductions: DNA plasmids were transiently
transfected in HT22 cells or HEK293T cells using Lipofectamine 2000 and Opti-MEM I.
SiRNA was transfected twice every 24h. After four to six hours post transfection, the
medium was replaced with new complete medium. Generally, cells were grown for 48h
after transfection prior to experimental assays. AAV9 variants were transduced to primary
neurons on DIV4 and were assayed for experiments on DIV18.

Cell/tissue lysis and immunoblotting
Cultured cells were lysed with RIPA lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 2 mM
EDTA, and 1% Triton X-100, 0.1% SDS) plus protease and phosphatase inhibitors. Brain
homogenates were lysed with RIPA buffer plus protease and phosphatase inhibitors with
sonication. Proteins were extracted and centrifuged at 15,000rpm for 15min at 4 oC, and
supernatants were used for Western blotting. Protein quantification was performed with
a colorimetric detection reagent (BCA protein assay, Pierce, Rockford, IL, USA). Equal
amounts of total protein were subjected to SDS-PAGE and transferred to nitrocellulose
membranes for immunoblotting. After probing with the primary antibody overnight at 4 °C,
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the corresponding peroxidase-conjugated secondary antibody was detected by ECL
western blot reagents (Pierce). ECL images were captured by the Fuji LAS-4000 imager
(LAS-4000, Pittsburgh, PA, USA) and quantified using the ImageJ software. All protein
amounts were normalized to actin prior to comparison between experimental conditions.

Immunofluorescence
For immunocytochemistry (ICC), cells were washed with PBS and fixed at room
temperature for 15 min with 4% paraformaldehyde (PFA). After washing with PBS, fixed
cells were incubated with blocking solution containing 0.2% Triton X-100, 3% normal goat
serum for 1h, followed by overnight incubation at 4°C with related primary antibodies.
After three washes with PBS, cells were incubated for 1h with Alexa-488, Alexa-594 or
Alexa-647 conjugated secondary IgG antibodies. Slides were then washed three times
with PBS and mounted with fluorochrome mounting solution. For immunohistochemistry
(IHC), mice were perfused with PBS, and half brains were immediately stored at -80℃ for
biochemical analysis, and the other half was fixed with 4% paraformaldehyde at 4℃ for
24 h followed by cryoprotection in 30% sucrose. Thirty-micron sections were blocked
using normal goat serum for 1h and subjected to primary antibodies at 4 ℃ overnight,
followed by secondary antibody (Alexa-488, Alexa-594 or Alexa-647) incubation for 1h at
room temperature prior to mounting. For PLA assays, Duolink® In Situ PLA® reagents
were purchased from Sigma-Aldrich. PLA assay was performed following the
manufacturer's instructions. All images from ICC, IHC, and PLA experiments were
captured with the Olympus FV10i confocal microscope (Tokyo, Japan).
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Plasmids and constructs
The mCherry-EGFP-p62 construct was generated by replacing the LC3B sequence with
the p62 sequence (pMXs-puro GFP-p62) from the pBABE-puro mCherry-EGFP-LC3B
construct using EcoRI and SalI restriction sites. The mCherry-EGFP-p62-S403A,
mCherry-EGFP-p62-S403E constructs were generated using the Agilent QuikChange II
Site-Directed Mutagenesis Kit from mCherry-EGFP-p62. SSH1, SSH1ΔC, SSH1ΔN were
subcloned into pN3-3XFlag vector using HindIII and SalI sites by PFU-based PCR
amplification of SSH1 from EGFP-SSH1 as a template. Flag-SSH1ΔN-C393S was
generated using the Agilent QuikChange II Site-Directed Mutagenesis Kit from FlagSSH1ΔN. Constructs used for recombinant proteins SSH1ΔC-his, SSH1ΔN-his, p62-his
were inserted into the backbone of pFastbac1 with XbaI and XhoI sites (addgene pDR125
removed LIG4 with XbaI and XhoI). All primers were custom designed as following and
ordered from IDT:
mCherry-EGFP-p62-FP: 5'-TTTTTGAATTCATGGCGTCGTTCACGGTGAAG-3'
mCherry-EGFP-p62-RP: 5'-TTTTTGTCGACTCACAATGGTGGAGGGTGCTT-3'
p62-S403A-FP: 5’-CTCTCCCAGATGCTGGCCATGGGTTTCTCGGAT-3’
p62-S403A-RP: 5’-ATCCGAGAAACCCATGGCCAGCATCTGGGAGAG-3’
p62-S403E-FP: 5’- CTCTCCCAGATGCTGGAGATGGGTTTCTCGGAT-3’
p62-S403E-RP: 5’-ATCCGAGAAACCCATCTCCAGCATCTGGGAGAG-3’
p62-his-FP: 5’-TTTTTGAATTCATGGCGTCGTTCACGGTGAAG–3’,
p62-his-RP: 5’-TTTTTCTCGAG CAATGGTGGAGGGTGCTTCGA-3’
SSH1ΔC-his-FP: 5’-TTTTTTCTAGAATGGCC CTGGTGACCCTGCAG-3’
SSH1ΔC-his-RP: 5’-TTTTTCTCGAGCTGCTGACGCCACAGCTT-3’
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SSH1ΔN-his-FP: 5’-TTTTTTCTAGAATGAAGCCCTCCCTTATCTTCGAT- 3’
SSH1ΔN-his-RP: 5’-TTTTTCTCGAGGCTTTTGCTCATCCACGAAGG-3’
Flag-SSH1-FP: 5’-TTTTTAAGCTTATGGCCCTGGTGACCTGCAG-3’
Flag-SSH1-RP: 5’-TTTTTGTCGACTCAGCTTTTGCTCATCCACGA-3’
Flag-SSH1ΔN-FP: 5’-TTTTTAAGCTTAAGCCCTCCCTTATCTTCGAT-3’
Flag-SSH1ΔN-RP: 5’-TTTTTGTCGACTCAGCTTTTGCTCATCCACGA-3’
Flag-SSH1ΔC-FP: 5’- TTTTTAAGCTTATGGCCCTGGTGACCTGCAG-3’
Flag-SSH1ΔC-RP: 5’-TTTTTGTCGACTCACTGCTGACGCCACAGCTT-3’
Flag-SSH1ΔN-C393S-FP: 5’-AAGTGCCTGGTGCATAGCAAAATGGGCGTGAGT-3’
Flag-SSH1ΔN-C393S-RP: 5’-ACTCACGCCCATTTTGCTATGCACCAGGCACTT-3’

Generation of rAAV9 and stereotaxic injections in mice
To generate the pTR12.1-MCSW-Flag-SSH1ΔN construct, Flag-SSH1ΔN was digested
by AgeI and SalI restriction enzymes and subcloned into the pTR12.1-MCSW vector
using AgeI and XhoI (destroyed after ligation) cloning sites. To generate the pTR12.1MCSW-ECFP-SSH1ΔC construct, the ECFP-SSH1 SSH1ΔC was cloned into pTR12.1MCSW vector at AgeI and NotI cloning sites. To generate the pTR12.1-MCSW -mCherryEGFP-p62 construct, the mCherry-EGFP-p62 digested by SpeI and SalI restriction
enzymes was cloned into the pTR12.1-MCSW vector using SpeI and XhoI (destroyed
after ligation) cloning sites. To generate H1rSC-SSH1-shRNA and H1rSC-SSH1-shRNAhrGFP constructs, the duplex of mouse SSH1 short hairpin RNA with the target sequence
5’-CCCGTTTAGATCACACCAGTA-3’ was cloned into H1rSC and H1rSC-hrGFP vectors
at ASCI and NheI cloning sites. Recombinant AAV9 viruses were generated by co-
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transfection of serotype vector expressing the gene of interest with pAAV9 and pXX6 in
HEK293 cells. Cells were lysed in the presence of 0.5% sodium deoxycholate, 1mM
MgCl2 and 50 U/ml Benzonase by freeze thawing after 48 hours incubation with
transfected vectors, and the virus was isolated using a discontinuous iodixanol
(OptiPrepTM Density Gradient Medium) gradient and purified with ApolloTM 20mL HighPerformance Centrifugal quantitative concentrators (Orbital Biosciences, Cat # 2015010)
(Carty et al., 2010; Woo et al., 2017a). For brain injections, isoflurane anesthetized mice
(3 months old, equally balanced for gender per condition) were bilaterally injected with a
26-gauge needle attached to a 10-μl syringe (Hamilton, Reno, NV, USA) at the following
coordinates: anteroposterior 2.7 mm, lateral 2.7 mm, and vertical 3.0 mm. A total volume
of 2 μl purified rAAV9 (1.3 × 1012vg/ml) was injected over a 2-min period using the
convection enhanced delivery method (Carty et al., 2010; Woo et al., 2017a). Mice were
sacrificed 8 weeks post injection.

Recombinant proteins
pFast-SSH1ΔC-his, pFast-SSH1ΔN-his, pFast-p62-his constructs were transformed into
DH10Bac competent cells. After blue-white screening, DH10Bac strains were chosen to
express and amplify recombinant Bacmids. Sf9 insect cells transfected with Bacmid
(midiprep from DH10Bac competent cells) were cultured for 3 days with Sf900 II SFM
medium, then P1 generation virus in medium was collected and added to new Sf9 cells.
After 2 days culture, Sf9 cells were harvested and lysed with lysis buffer (Tris 20mM,
pH7.4, NaCl 150mM, Triton-X100 1%, 10mM imidazole, with protease inhibitors). After
centrifugation at 12,000g for 15 minutes, supernatant was collected and shaken for 1 hour
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at 4oC with GE Healthcare Ni Sepharose. Bound proteins on sepharose were washed 3
times with ice-cold lysis buffer, and recombinant proteins were eluted with ice-cold elution
buffer (Tris 20mM, NaCl 150mM, 200mM imidazole), after which proteins were dialyzed
in dialysis buffer (Tris 20mM, NaCl 150mM, DTT 1mM) at 4°C overnight.

Quantification and Statistical Analysis
Immunofluorescence images were quantified by using the Image J software (National
Institutes of Health, Bethesda, MD). All comparison images were acquired with identical
laser intensity, exposure time, and filter. Adjustments to the brightness/contrast and
threshold were applied equally to all comparison images. Regions of interest (ROI) for
cell lines and primary neurons were cell body (excluded cell nuclei). ROI for brain tissue
were chosen randomly throughout the CA3 region of the hippocampus. All puncta
numbers were quantified manually with the Image J cell counter plugin. Puncta sizes were
measured as particle area with Image J Analyze Particles. All percentages of colocalization were measured with Image J COLOC2 Manders’ Correlation with in-program
threshold. Investigators were blinded to genotypes of mice and experimental conditions
during image acquisition and quantification. Statistical data were analyzed by the
GraphPad Prism 6.0 software using Student's t-test, 2 test for trend, 1-way ANOVA, or
2-way ANOVA. ANOVA was followed by Tukey’s or Sidak’s posthoc test. All quantitative
graphs were expressed as means ± S.E.M. Differences were deemed significant when
P<0.05.
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SUPPLEMENTAL INFORMATION

Supplemental Figure S1 A-F. SSH1-mediated inhibition of p62 underlines LC3 suppression,
Related to Figure 9
A. Representative images at 4h FCCP condition with white insets magnified. HT22 cells cotransfected with GFP-OPTN and vector control (p3xFlag) or Flag-SSH1, treated with 5µM FCCP
for 4h, 2h, and 0h (DMSO), and subjected to staining for Flag-M2 (light blue) and Tom20 (red) or
direct imaging for GFP-OPTN (green).
B-C. Quantitative graphs of figure A expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=20/condition from 3 different experiments.
D. Representative images at 4h FCCP condition with white insets magnified. HT22 cells cotransfected with GFP-p62 and vector control (p3xFlag) or Flag-SSH1, treated with 5µM FCCP for
4h, 2h, and 0h (DMSO), and subjected to staining for Flag-M2 (light blue) and Tom20 (dark blue)
or direct imaging for GFP-p62 (green). Tom20 pseudocolored to red with GFP-p62 overlay.
E-F. Quantitative graphs of figure D expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=20/condition from 3 different experiments, *p<0.05, **p<0.005, #p<0.0001.
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Supplemental Figure S1 G-I. SSH1-mediated inhibition of p62 underlines LC3 suppression,
Related to Figure 9
G. Representative images at 4h FCCP condition with white insets magnified. HT22 cells cotransfected with GFP-p62 and mito-dsRed together with vector control siRNA or SSH1 siRNA,
treated with 5µM FCCP for 4h, 2h, and 0h (DMSO), and subjected to staining for SSH1 (dark blue)
or direct imaging for GFP-p62 (green) and mito-dsRed (red).
H-I. Quantitative graph of figure G expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=15/condition from 3 different experiments, *p<0.05, **p<0.005, #p<0.0001.

Supplemental Figure S2. SSH1 decreases p62 Ser403 phosphorylation and inhibits p62ubiquntin binding, related to Figure 10
A. Representative PLA negative control images using only 1 primary antibody or 1 secondary
probe from HT22 cells with GFP (see Figure 10 J).
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Supplemental Figure S3 A-C. SSH1-mediated p62 inhibition requires pSer403 modification
of p62, Related to Figure 11
A. Schematic of p62 full length, truncated, and mutant forms.
B. Representative images at 4h FCCP condition from HT22 cells co-transfected with RFP-LC3
and GFP-P62ΔC together with vector control (p3xFlag) or Flag-SSH1, treated with 5µM FCCP for
4h, 2h, 0.5h, or 0h (DMSO), and subjected to staining for Flag-M2 (light blue) and Tom20 (dark
blue) or direct imaging for GFP-p62ΔC (green) and RFP-LC3 (red).
C. Quantitative graph of figure B expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=15/condition from 3 different experiments.
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Supplemental Figure S3 D-G. SSH1-mediated p62 inhibition requires pSer403 modification
of p62, Related to Figure 11
D. Representative images at 4h FCCP condition from HT22 cells co-transfected with RFP-LC3
and GFP-P62-LIR together with vector control (p3xFlag) or Flag-SSH1, treated with 5µM FCCP
for 4h, 2h, 0.5h, or 0h (DMSO), and subjected to staining for Flag-M2 (dark blue) and Tom20 (light
blue) or direct imaging for GFP-p62-LIR (green). Tom20 pseudo-colored to red with GFP-p62-LIR
overlay.
E-F. Quantitative graph of figure E expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=10/condition from 3 different experiments, *p<0.05, **p<0.005, ***p<0.0005,
#p<0.0001.
G. Representative blots from co-IP of GFP-p62 in HA-p62 immune complexes in HT22 cells cotransfected with vector control (p3xFlag) or Flag-SSH1 + GFP-p62 and/or HA-p62. IgG indicates
IgG beads only.
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Supplemental Figure S3 H-L. SSH1-mediated p62 inhibition requires pSer403 modification
of p62, Related to Figure 11
H. Representative images from HT22 cells co-transfected with GFP-p62 and HA-p62 together
with vector control (p3xFlag) or Flag-SSH1, and subjected to in situ PLA for GFP-p62/HA-p62
complexes (red) using antibodies against GFP and HA, and staining for Flag-M2 (dark blue) and
DAPI (light blue).
I. Quantitative graph of figure H expressed as means ±SEM, t-test, n=10/condition from 3 different
experiments.
J. Representative images from 4h FCCP condition with white insets magnified. HT22 cells cotransfected with GFP-p62-S403A and mito-dsRed together with control shRNA or SSH1-shRNA,
treated with 5µM FCCP for 4h and 0h (DMSO), and subjected to staining for SSH1 (dark blue)
and DAPI (light blue) or directing imaging for GFP-p62 (green) and mito-dsRed (red).
K-L. Quantitative graph of figure K expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=15/condition from 3 different experiments.
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Supplemental Figure S3 M-Q. SSH1-mediated p62 inhibition requires pSer403 modification
of p62, Related to Figure 11
M. Representative images from 4h FCCP condition with white insets magnified. HT22 cells cotransfected with GFP-p62-S403E and mito-dsRed together with control shRNA or SSH1-shRNA,
treated with 5µM FCCP for 4h and 0h (DMSO), and subjected to staining for SSH1 (dark blue)
and DAPI (light blue) or directing imaging for GFP-p62 (green) and mito-dsRed (red).
N-O. Quantitative graph of figure M expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=15/condition from 3 different experiments.
P-Q. Quantitative graph of figure 11 G expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=15/condition from 3 different experiments, *p<0.05, ***p<0.0005, #p<0.0001.
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Supplemental Figure S4. Direct dephosphorylation of pSer403-p62 by SSH1 is separable
from cofilin dephosphorylation, related to Figure 12
A. Representative blots showing co-IP of Flag-SSH1 and SSH1ΔN in GFP-p62 immune
complexes from HT22 cells co-transfected with GFP-p62 and vector control (p3xFlag), Flag-SSH1,
or Flag-SSH1ΔN.
B. Quantitative graph of figure A1 expressed as means ± SEM, t-test, *p<0.05.
C. Representative images of 4h FCCP condition with white insets magnified. HT22 cells cotransfected with GFP-p62 and control (p3xFlag), Flag-SSH1ΔN, or Flag-SSH1ΔN-CS, treated
with 5µM FCCP for 4h, 2h, 0.5h, or 0h (DMSO), and subjected to staining for Flag-M2 (light blue)
and Tom20 (red) or direct imaging for GFP-p62 (green).
D-E. Quantitative graphs of figure C expressed as means ± SEM, two-way ANOVA with Tukey's
posthoc test, n=15/condition from 3 different experiments, *p<0.05, #p<0.0001.
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Supplemental Figure S5. Endogenous SSH1 and SSH1ΔN impair p62 flux and ubiquitin
binding in primary neurons, Related to Figure 13
A. Representative blots of SSH1ΔN expression and pSer403-p62 in neurons transduced with
control or Flag-SSH1ΔN AAV9.
B. Representative blots of SSH1 expression and pSer403-p62 in neurons transduced with control
shRNA or SSH1-shRNA AAV9.
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